Precigen (PGEN) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 20, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-K	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'
Trading Symbol	'XON	'
Entity Registrant Name	'INTREXON CORP	'
Entity Central Index Key	'0001356090	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	97,794,655
Entity Public Float	$814,400,000	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$49,509	$10,403
Short-term investments	127,980	260
Receivables	'	'
Trade	790	141
Related parties	5,285	531
Other	1,282	35
Prepaid expenses and other	2,710	2,163
Total current assets	187,556	13,533
Long-term investments	60,581	'
Property, plant and equipment, net	16,629	18,687
Intangible assets, net	41,956	29,506
Goodwill	13,823	'
Investments in affiliates	6,284	5,726
Other assets	1,118	1,078
Total assets	469,472	151,646
Current liabilities	'	'
Accounts payable	1,057	632
Accrued compensation and benefits	5,157	3,766
Other accrued liabilities	4,187	2,208
Deferred revenue	7,793	9,963
Capital lease obligations, current	30	49
Related party payables	1,605	99
Total current liabilities	19,829	16,717
Capital lease obligations, net of current portion	10	42
Long term debt	1,653	'
Deferred revenue	65,778	48,673
Other long term liabilities	859	1,108
Total liabilities	88,129	66,540
Commitments and contingencies (Note 14)	'	'
Total equity (deficit)	'	'
Common stock, no par value, 200,000,000 shares and 160,000,000 shares authorized as of December 31, 2013 and 2012, respectively; and 97,053,712 shares and 5,661,525 shares issued and outstanding as of December 31, 2013 and 2012, respectively	'	'
Additional paid-in capital	743,084	'
Accumulated deficit	-376,414	-321,553
Accumulated other comprehensive income	52	'
Total Intrexon shareholders' equity (deficit)	366,722	-321,553
Noncontrolling interests	14,621	'
Total equity (deficit)	381,343	-321,553
Total liabilities, redeemable convertible preferred stock and total equity (deficit)	469,472	151,646
Series A Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	1,358
Series B Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	669
Series B-1 Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	1,360
Series C Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	7,134
Series C-1 Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	34,201
Series C-2 Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	44,512
Series C-3 Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	29,770
Series D Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	76,252
Series E Redeemable Convertible Preferred Stock	'	'
Current liabilities	'	'
Redeemable convertible preferred stock	'	211,403
Collaborative Partner Securities	'	'
Receivables	'	'
Equity securities	$141,525	$83,116

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

In Thousands, except Share data, unless otherwise specified

Series A Redeemable Convertible Preferred Stock

Series A Redeemable Convertible Preferred Stock

Series B Redeemable Convertible Preferred Stock

Series B Redeemable Convertible Preferred Stock

Series B-1 Redeemable Convertible Preferred Stock

Series B-1 Redeemable Convertible Preferred Stock

Series C Redeemable Convertible Preferred Stock

Series C Redeemable Convertible Preferred Stock

Series C-1 Redeemable Convertible Preferred Stock

Series C-1 Redeemable Convertible Preferred Stock

Series C-2 Redeemable Convertible Preferred Stock

Series C-2 Redeemable Convertible Preferred Stock

Series C-3 Redeemable Convertible Preferred Stock

Series C-3 Redeemable Convertible Preferred Stock

Series D Redeemable Convertible Preferred Stock

Series D Redeemable Convertible Preferred Stock

Series E Redeemable Convertible Preferred Stock

Series E Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock, par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redeemable convertible preferred stock, stated value

'

'

'

$1.21

'

$0.72

'

$0.83

'

$1.10

'

$1.57

'

$1.88

'

$1.88

'

$3.38

'

$5.25

Liquidation preference

'

'

'

$1,406

'

$709

'

$1,380

'

$7,162

'

$34,222

'

$44,614

'

$29,819

'

$76,347

'

$214,086

Redeemable convertible preferred stock, shares authorized

'

'

'

705,400

'

694,000

'

1,212,360

'

4,546,360

'

15,934,528

'

18,617,020

'

13,297,872

'

19,803,685

'

38,095,239

Redeemable convertible preferred stock, shares issued

'

'

'

705,400

'

694,000

'

1,212,360

'

4,546,360

'

15,934,528

'

18,617,020

'

13,297,872

'

19,803,685

'

38,095,239

Redeemable convertible preferred stock, shares outstanding

'

'

'

705,400

'

694,000

'

1,212,360

'

4,546,360

'

15,934,528

'

18,617,020

'

13,297,872

'

19,803,685

'

38,095,239

Common stock, par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

200,000,000

160,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

97,053,712

5,661,525

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares Outstanding

97,053,712

5,661,525

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	'	'	'
Collaboration revenues	$23,525	$13,706	$5,118
Other revenues	235	68	2,895
Total revenues	23,760	13,774	8,013
Operating Expenses	'	'	'
Research and development	48,165	64,034	70,228
General and administrative	33,618	24,897	18,300
Other	'	'	1,912
Total operating expenses	81,783	88,931	90,440
Operating loss	-58,023	-75,157	-82,427
Other Income (Expense)	'	'	'
Unrealized appreciation (depreciation) in fair value of equity securities	10,443	-6,290	-2,675
Gain in previously held equity investment	7,415	'	'
Interest expense	-141	-57	-183
Investment income	166	5	6
Other expense	-162	-101	-1
Total other income (expense)	17,721	-6,443	-2,853
Equity in net loss of affiliates	-606	-274	'
Net loss	-40,908	-81,874	-85,280
Net loss attributable to the noncontrolling interests	1,928	'	'
Net loss attributable to Intrexon	-38,980	-81,874	-85,280
Accretion of dividends on redeemable convertible preferred stock	-18,391	-21,994	-13,868
Net loss attributable to common shareholders	($57,371)	($103,868)	($99,148)
Net loss attributable to common shareholders per share, basic and diluted	($1.40)	($18.77)	($18.92)
Weighted average shares outstanding, basic and diluted	40,951,952	5,533,690	5,240,647

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net loss	($40,908)	($81,874)	($85,280)
Other comprehensive income:	'	'	'
Unrealized gain on investments	21	'	'
Foreign currency translation adjustments	58	'	'
Comprehensive loss	-40,829	-81,874	-85,280
Comprehensive loss attributable to the noncontrolling interests	1,901	'	'
Comprehensive loss attributable to Intrexon	($38,928)	($81,874)	($85,280)

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' and Total Equity (Deficit) (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Intrexon shareholders' equity (deficit)	Noncontrolling Interests
In Thousands, except Share data	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Beginning balance at Dec. 31, 2010	($127,734)	'	'	'	($127,734)	($127,734)	'
Beginning balance, shares at Dec. 31, 2010	'	2,357,494	'	'	'	'	'
Stock-based compensation expense	983	'	983	'	'	983	'
Exercises of stock options	184	'	184	'	'	184	'
Exercises of stock options, shares	'	75,840	'	'	'	'	'
Acquisitions	4,237	'	4,237	'	'	4,237	'
Acquisitions, shares	'	3,019,294	'	'	'	'	'
Contribution of services by shareholder	210	'	210	'	'	210	'
Shares issued to nonemployee members of the Board of Directors	9	'	9	'	'	9	'
Shares issued to nonemployee members of the Board of Directors, shares	'	1,265	'	'	'	'	'
Accretion of dividends on redeemable convertible preferred stock	-13,868	'	-5,623	'	-8,245	-13,868	'
Net loss	-85,280	'	'	'	-85,280	-85,280	'
Ending balance at Dec. 31, 2011	-221,259	'	'	'	-221,259	-221,259	'
Ending balance, shares at Dec. 31, 2011	'	5,453,893	'	'	'	'	'
Stock-based compensation expense	1,458	'	1,458	'	'	1,458	'
Exercises of stock options	473	'	473	'	'	473	'
Exercises of stock options, shares	'	194,570	'	'	'	'	'
Contribution of services by shareholder	1,550	'	1,550	'	'	1,550	'
Shares issued to nonemployee members of the Board of Directors	93	'	93	'	'	93	'
Shares issued to nonemployee members of the Board of Directors, shares	'	13,062	'	'	'	'	'
Accretion of dividends on redeemable convertible preferred stock	-21,994	'	-3,574	'	-18,420	-21,994	'
Net loss	-81,874	'	'	'	-81,874	-81,874	'
Ending balance at Dec. 31, 2012	-321,553	'	'	'	-321,553	-321,553	'
Ending balance, shares at Dec. 31, 2012	5,661,525	5,661,525	'	'	'	'	'
Shares issued in IPO, value	168,801	'	168,801	'	'	168,801	'
Shares issued in IPO, shares	'	11,499,998	'	'	'	'	'
Stock-based compensation expense	2,921	'	2,812	'	'	2,812	109
Exercises of stock options and warrant, value	414	'	410	'	'	410	4
Exercises of stock options and warrant, shares	'	176,531	'	'	'	'	'
Contribution of services by shareholder	1,550	'	1,550	'	'	1,550	'
Shares issued to nonemployee members of the Board of Directors	124	'	124	'	'	124	'
Shares issued to nonemployee members of the Board of Directors, shares	'	10,595	'	'	'	'	'
Accretion of dividends on redeemable convertible preferred stock	-18,391	'	-2,510	'	-15,881	-18,391	'
Conversion of redeemable convertible preferred shares, including accrued dividends, to common stock, value	571,898	'	571,898	'	'	571,898	'
Conversion of redeemable convertible preferred shares, including accrued dividends, to common stock, shares	'	79,705,130	'	'	'	'	'
Settlement of fractional shares from reverse stock split, value	-1	'	-1	'	'	-1	'
Settlement of fractional shares from reverse stock split, shares	'	-67	'	'	'	'	'
Adjustments for noncontrolling interests	16,409	'	'	'	'	'	16,409
Net loss	-40,908	'	'	'	-38,980	-38,980	-1,928
Other comprehensive income	79	'	'	52	'	52	27
Ending balance at Dec. 31, 2013	$381,343	'	$743,084	$52	($376,414)	$366,722	$14,621
Ending balance, shares at Dec. 31, 2013	97,053,712	97,053,712	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities	'	'	'
Net loss	($40,908)	($81,874)	($85,280)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	7,205	7,984	4,338
Loss on disposal of property and equipment	349	101	1
Unrealized (appreciation) depreciation on equity securities	-10,443	6,290	2,675
Amortization of discount/premium of investments	716	'	'
Collaboration revenue recognized upon achievement of milestone	'	-3,591	'
Equity in net loss of affiliates	606	274	'
Gain in previously held equity investment	-7,415	'	'
Stock-based compensation expense	2,921	1,458	983
Contribution of services by shareholder	1,550	1,550	210
Shares issued to nonemployee members of the Board of Directors	124	93	9
Other noncash items	-75	'	'
Receivables:	'	'	'
Trade	-644	-121	33
Related parties	-4,967	-93	-239
Other	-542	1,015	-400
Prepaid expenses and other	-347	-413	-772
Other assets	-18	658	-614
Accounts payable	-43	-1,229	-388
Accrued compensation and benefits	1,301	2,441	-2,249
Other accrued liabilities	1,558	-806	1,204
Deferred revenue	-4,368	4,997	-2,245
Related party payables	6	-180	-215
Other long term liabilities	-249	-83	1,191
Net cash used in operating activities	-53,683	-61,529	-81,758
Cash flows from investing activities	'	'	'
Purchases of investments	-233,979	-2	-188
Maturities of investments	44,996	'	'
Purchases of equity securities	-28,650	-10,000	-22,628
Acquisitions of businesses, net of cash received	517	'	-28,662
Investments in affiliates	-5,000	-6,000	'
Purchases of property and equipment	-1,527	-7,491	-13,003
Proceeds from sale of property and equipment	480	23	84
Issuance of notes receivable	-1,000	-200	'
Proceeds from related party notes receivable	500	34	300
Net cash used in investing activities	-223,663	-23,636	-64,097
Cash flows from financing activities	'	'	'
Proceeds from IPO, net of issuance costs	168,801	'	'
Proceeds from issuance of subscriptions payable	'	'	7,440
Settlement of fractional shares	-5	'	'
Proceeds from short-term borrowings	'	'	15,000
Payments of capital lease obligations	-51	-77	-115
Proceeds from long term debt	493	'	'
Payments of long term debt	-53	'	'
Proceeds from stock option exercises	414	473	184
Payment of preferred stock issuance costs	-3,148	-16	-2,675
Net cash provided by financing activities	316,451	75,940	148,111
Effect of exchange rate changes on cash and cash equivalents	1	'	'
Net increase (decrease) in cash and cash equivalents	39,106	-9,225	2,256
Cash and cash equivalents	'	'	'
Beginning of period	10,403	19,628	17,372
End of period	49,509	10,403	19,628
Supplemental disclosure of cash flow information	'	'	'
Cash paid during the period for interest	51	12	18
Significant noncash financing and investing activities	'	'	'
Accretion of dividends on redeemable convertible preferred shares	18,391	21,994	13,868
Stock received as upfront consideration for collaboration agreements	19,303	21,979	19,144
Stock received as consideration upon achievement of milestone	'	18,330	'
Equity instruments issued in acquisitions	'	'	4,237
Accrued investment in affiliate	1,500	'	'
Purchases of equipment included in accounts payable and other accrued liabilities	361	24	2,231
Series D Redeemable Convertible Preferred Stock	'	'	'
Cash flows from financing activities	'	'	'
Proceeds from issuance of redeemable convertible preferred shares	'	'	26,442
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	79,078	'	'
Accretion of dividends on redeemable convertible preferred shares	2,827	4,328	'
Series E Redeemable Convertible Preferred Stock	'	'	'
Cash flows from financing activities	'	'	'
Proceeds from issuance of redeemable convertible preferred shares	'	75,560	101,835
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	219,332	'	'
Accretion of dividends on redeemable convertible preferred shares	7,931	10,465	'
Series F Redeemable Convertible Preferred Stock	'	'	'
Cash flows from financing activities	'	'	'
Proceeds from issuance of redeemable convertible preferred shares	150,000	'	'
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	150,075	'	'
Accretion of dividends on redeemable convertible preferred shares	3,224	'	'
Subscriptions Payable | Series D Redeemable Convertible Preferred Stock	'	'	'
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	'	'	2,500
Subscriptions Payable | Series E Redeemable Convertible Preferred Stock	'	'	'
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	'	7,440	'
Short Term Borrowing | Series E Redeemable Convertible Preferred Stock	'	'	'
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	'	'	15,165
Common Shares Issuable Upon Conversion of All Series Preferred | Common Stock	'	'	'
Significant noncash financing and investing activities	'	'	'
Conversion of liabilities into redeemable convertible preferred shares and conversion of redeemable convertible preferred shares, including accrued dividends, to common stock	$571,898	'	'

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	1. Organization and Basis of Presentation
	Intrexon Corporation (the “Company” or “Intrexon”) is a Virginia corporation focused on forming collaborations to create biologically based products and processes using synthetic biology. At December 31, 2013, the Company owned approximately 54% of AquaBounty Technologies, Inc. (“AquaBounty”), a biotechnology company focused on improving productivity in commercial aquaculture (Note 7), and 51% of Biological & Popular Culture, Inc. (“BioPop”) (Note 3). The Company has operations in California, Florida, Maryland, North Carolina and Virginia. There have been no commercialized products derived from the Company’s collaborations to date.
	Effective July 26, 2013, the Company’s board of directors and shareholders approved a reverse stock split of 1-for-1.75 of the Company’s shares of common stock. Shareholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Shares of common stock underlying outstanding stock options and warrants were proportionately reduced and the respective exercise prices were proportionately increased in accordance with the terms of the agreements governing such securities. All share and per share data of the Company’s common stock, including shares of common stock underlying stock options and warrants, have been retroactively adjusted in the accompanying consolidated financial statements to reflect the reverse stock split.
	On August 13, 2013, the Company completed its initial public offering (“IPO”), whereby the Company sold 11,499,998 shares of common stock, inclusive of 1,499,999 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the IPO, at a price of $16.00 per share. The shares began trading on the New York Stock Exchange (“NYSE”) on August 8, 2013. The aggregate proceeds from the IPO were approximately $168,300, net of underwriting discounts and commissions of approximately $12,900 and offering expenses paid by the Company of approximately $2,800 (of which $2,300 were capitalized). Upon the closing of the IPO, all shares of the Company’s redeemable convertible preferred stock, including accrued but unpaid dividends thereon, converted into 79,705,130 shares of common stock. Additionally, in connection with the closing of the IPO, the Company amended and restated its articles of incorporation to increase the number of authorized shares of common stock to 200,000,000 and decrease the number of authorized shares of undesignated preferred stock to 25,000,000.
	These consolidated financial statements are presented in U.S. dollars and are prepared under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
	Revenue Recognition
	The Company generates revenue through contractual agreements with collaborative partners (known as exclusive channel collaborations, “ECC” or “ECCs”) whereby the partners obtain exclusive access to the Company’s proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these collaborative agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific application provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration.
	The Company’s collaboration agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. Effective January 1, 2011, the Company adopted the provisions of Accounting Standards Update (“ASU”) No. 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements (“ASU 2009-13”). In accordance with the provisions of ASU 2009-13, the Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborative partner on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.
	Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price (“BESP”) for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.
	The terms of the Company’s agreements may provide for milestone payments upon achievement of certain defined events. The Company applies ASU No. 2010-17, Revenue Recognition — Milestone Method (“ASU 2010-17” or “Milestone Method”). Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
	-1	The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;
	-2	The consideration relates solely to past performance; and
	-3	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
	In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.
	Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.
	Research and Development
	The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, and the costs of consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
	The Company has research and development arrangements with third parties that include upfront and milestone payments. At December 31, 2013 and 2012, the Company had research and development commitments with third parties totaling $2,445 and $3,164, respectively, of which $957 and $1,431, respectively, had not yet been incurred. The commitments are generally cancellable by the Company at any time upon written notice.
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. At December 31, 2013 and 2012, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $43,733 and $9,384, respectively.
	Short-term and Long-term Investments
	Short-term and long-term investments include U.S. government debt securities, commercial paper and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management’s reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company’s written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor’s, Moody’s and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
	Equity Securities
	The Company holds equity securities received and/or purchased from certain collaborative partners. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these partners. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborative partners. These equity securities are classified as noncurrent in the consolidated balance sheet as the Company does not intend to sell these equity securities within one year. The Company has not sold any of these equity securities to date.
	The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator’s security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
	Fair Value of Financial Instruments
	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
	Level 1		Quoted prices in active markets for identical assets and liabilities;
	Level 2		Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and
	Level 3		Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
	Concentrations of Risk
	Due to the Company’s mix of fixed and variable rate securities holdings, the Company’s investment portfolio is susceptible to changes in interest rates. As of December 31, 2013, the Company’s investments had gross unrealized losses of $14. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.
	Equity Method Investments
	Through March 15, 2013, the Company accounted for its investment in AquaBounty using the equity method of accounting since the Company had the ability to exercise significant influence, but not control, over the operating activities of AquaBounty. The excess of the investment over the Company’s pro-rata share of AquaBounty’s net assets represented identifiable intangible assets and equity-method goodwill. On March 15, 2013, the Company acquired additional ownership interests in AquaBounty which resulted in the Company gaining control over AquaBounty, thereby requiring consolidation effective on that date (Note 7).
	The Company applied the equity method of accounting to account for its investment in S & I Ophthalmic, LLC (“S & I Ophthalmic”), a joint venture between the Company and an indirect subsidiary (“Sun Pharmaceutical Subsidiary”) of Sun Pharmaceutical Industries Ltd. (“Sun Pharmaceutical”), an international specialty pharmaceutical company focused on chronic diseases. The Company also applied the equity method of accounting to its investment in OvaXon, LLC (“OvaXon”), a joint venture between the Company and OvaScience Inc. (“OvaScience”), a life sciences company focused on infertility treatments (Note 8). The Company accounts for its investments in S & I Ophthalmic and OvaXon using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities. See Note 8 for additional discussion of S & I Ophthalmic and OvaXon.
	The Company determined that it has significant influence over two and one of its collaborators as of December 31, 2013 and 2012, respectively, based on its ownership interest, representation on the board of directors of the collaborator and other qualitative factors. As of December 31, 2012, the Company determined that one of these collaborators, Ziopharm Oncology, Inc. (“Ziopharm”), met the criteria of SEC Regulation S-X Article 3-09 for inclusion of separate financial statements of an equity method investment. The Company accounts for this investment using the fair value option. The fair value of the Company’s equity securities of Ziopharm was $71,134 and $56,298 as of December 31, 2013 and 2012, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company’s ownership interest in Ziopharm was 16.4% and 16.3% at December 31, 2013 and 2012, respectively. Unrealized appreciation (depreciation) in the fair value of the Company’s equity securities held in Ziopharm was $4,836, $(7,194), and $(4,924) for the years ended December 31, 2013, 2012 and 2011, respectively.
	In September 2013, the Company increased its investment in Oragenics, Inc. (“Oragenics”) resulting in the Company concluding it had significant influence over the operations of Oragenics. The fair value of the Company’s equity securities of Oragenics was $22,161 and $10,129 as of December 31, 2013 and 2012, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company’s ownership interest in Oragenics was 24.6% and 16.0% at December 31, 2013 and 2012, respectively. Unrealized appreciation (depreciation) in the fair value of the Company’s equity securities held in Oragenics was $(90) and $3,540 for the years ended December 31, 2013 and 2012, respectively. Summarized financial data for Oragenics as of December 31, 2013 and for the years ended December 31, 2013 and 2012 are as follows:
			December 31,
			2013
	Current assets		$	16,805
	Non-current assets			27
	Total assets			16,832
	Current liabilities			993
	Net assets		$	15,839
			Year ended
			December 31,
			2013			2012
	Revenues, net		$	1,032		$	1,332
	Gross profit			689			454
	Loss from operations			(16,210	)		(12,432	)
	Net loss		$	(16,069	)		(13,090	)
	Variable Interest Entities
	The Company identifies entities that (1) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (2) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are a VIE. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (1) the power to direct activities that most significantly impact the VIE’s economic performance and (2) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of December 31, 2012, the Company determined that its investment in AquaBounty was a VIE. The Company was not the primary beneficiary for this entity since it did not have the power to direct the activities that most significantly impact the economic performance of the VIE. As of December 31, 2012, the total carrying value of the Company’s investment in the VIE was $5,726, which is the investment in AquaBounty. On March 15, 2013, the Company began consolidating AquaBounty since the Company’s ownership in AquaBounty exceeded 50% (Note 7). The Company’s maximum exposure to loss related to this VIE was limited to the carrying value of the investment.
	As of December 31, 2013, the Company determined that one of the its collaborators, Genopaver, LLC (“Genopaver”), was a VIE. The Company was not the primary beneficiary for this entity since it did not have the power to direct the activities that most significantly impact the economic performance of the VIE.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:
			Years
	Building			13
	Furniture and fixtures			7
	Lab equipment			2–7
	Computer hardware			5–7
	Software			3–5
	Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to four years.
	Goodwill
	Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Notes 3 and 7). Goodwill is reviewed for impairment at least annually. The Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.
If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.
The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets
Intangible assets subject to amortization consist of patents and related technologies acquired as a result of mergers and acquisitions (Note 3). These intangible assets are subject to amortization and were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in a step acquisition (Note 7) and was recorded at fair value at the date of the step acquisition.
The Company applies the provisions of ASC Topic 350, Intangibles, Goodwill and Other, which requires the amortization of long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from seven to fourteen years for the patents and related technologies.
Impairment of Long-Lived Assets
Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in general and administrative expenses.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information
The Company has determined that it operates in one segment. The Company uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company’s revenues are derived in the United States of America. Substantially all of the Company’s assets are located in the United States of America.
Recently Issued Accounting Pronouncements
In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, companies would instead cross reference to the related footnote for additional information. ASU 2013-02 is effective for interim and annual reporting periods beginning after December 15, 2012. The Company has implemented the provisions of ASU 2013-02 as of January 1, 2013. The adoption of this amendment did not have a material impact on the Company’s consolidated financial statements.
In July 2012, the FASB issued guidance intended to simplify indefinite-lived intangible impairment testing, by allowing an entity to first assess qualitative factors to determine whether it is “more likely than not” that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim tests performed for fiscal years beginning after September 15, 2012. The adoption of this guidance did not impact the Company’s consolidated financial statements.
In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”). ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (“IFRS”). The new standards are effective for annual periods beginning January 1, 2013 and interim periods within those annual periods. Retrospective application is required. The Company has implemented the provisions of ASU 2011-11 as of January 1, 2013. The adoption of this amendment did not have a material impact on the Company’s consolidated financial statements.
Reclassifications
Certain insignificant reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Mergers_and_Acquisitions

Mergers and Acquisitions	12 Months Ended
	Dec. 31, 2013
Mergers and Acquisitions	'
	3. Mergers and Acquisitions
	Agarigen, Inc.
	On January 26, 2011, the Company acquired 100% of the outstanding common stock of Agarigen, Inc. (“Agarigen”), a North Carolina-based company which developed a novel mushroom-based platform for the production of proteins, by merging Agarigen into a newly formed wholly-owned subsidiary. The acquisition allows the Company to combine Agarigen’s technology with the Company’s technology and capability in a specific agricultural sector. As consideration for the acquisition, the Company paid $1,178 cash and issued 386,142 shares of its common stock at closing. The Company also issued 165,255 options to purchase the Company’s common stock at strike prices ranging from $0.38 to $1.98 and issued warrants to purchase up to 511,098 shares of the Company’s common stock at a price per share of $0.79. The results of Agarigen’s operations subsequent to January 26, 2011 have been included in the consolidated financial statements.
	The fair value of the total consideration transferred was $3,773. The acquisition date fair value of each class of consideration transferred was as follows:
	Cash	$	1,178
	Common shares		1,014
	Stock options and warrants		1,581
		$	3,773
	The fair value of the shares of the Company’s common stock issued was based upon the value of the Company’s common stock at the acquisition date determined under an option-pricing method as prescribed by the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (“AICPA Practice Aid”). The option-pricing method treats common stock and preferred stock as call options on the enterprise’s equity value, with exercise prices based on the liquidation preferences of the preferred stock. The fair value of stock options and warrants issued were determined in accordance with ASC Topic 718, Compensation — Stock Compensation. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	334
	Trade receivables		53
	Other receivables		436
	Prepaid expenses and other		11
	Property and equipment		30
	Intangible assets		3,122
	Other assets		3
	Total assets acquired		3,989
	Accounts payable		60
	Accrued compensation and benefits		65
	Other accrued liabilities		91
	Total liabilities assumed		216
	Net assets acquired	$	3,773
	The fair value of acquired intangible assets was determined using the relief-from-royalty method, a variation of the income approach that estimates the benefit of owning the intangible assets rather than paying royalties for the right to use comparable assets. The acquired intangible assets are being amortized over the expected useful life of nine years and consist of acquired patents and related technology.
	The Company paid $110 of acquisition related costs, which are included in general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2011.
	The warrants were fully vested upon issuance, have an exercise price of $0.79 per share and expire in December 2017. The Company considered the applicable provisions of ASC No. 480, Distinguishing Liabilities and Equity, and ASC No. 815, Derivatives and Hedging, and determined the warrants should be classified as shareholders’ equity.
	GT Life Sciences, Inc.
	On October 5, 2011, the Company acquired 100% of the outstanding common stock of GT Life Sciences, Inc. (“GT Life”), a California company, by merging a newly formed wholly-owned subsidiary with and into GT Life. The acquisition allows the Company to combine GT Life’s technology with the Company’s technology and capability for the development and deployment of high value production cell lines. The Company paid $14,250 cash at closing, which was the acquisition date fair value of the total consideration transferred. The results of GT Life’s operations subsequent to October 5, 2011 have been included in the consolidated financial statements.
	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	21
	Other receivables		161
	Related party receivable		33
	Prepaid expenses and other		1
	Property and equipment		32
	Intangible assets		14,094
	Total assets acquired		14,342
	Accounts payable		55
	Accrued compensation and benefits		29
	Other accrued liabilities		8
	Total liabilities assumed		92
	Net assets acquired	$	14,250
	The fair value of acquired intangible assets was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to the intangible asset. The acquired intangible assets are being amortized over the expected useful life of thirteen years and consist of acquired patents and related technology.
	The Company paid $276 of acquisition related costs, which are included in general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2011.
	Immunologix, Inc.
	On October 21, 2011, the Company acquired 100% of the outstanding preferred and common stock of Immunologix, Inc. (“Immunologix”), a South Carolina-based company specializing in therapeutic antibodies, by merging a newly formed wholly-owned subsidiary with and into Immunologix. The acquisition allows the Company to combine Immunologix’s antibody technology with the Company’s existing technology and capability. The Company paid $12,758 cash and issued 153,365 shares of its common stock at closing. The results of Immunologix’s operations from October 21, 2011 have been included in the consolidated financial statements.
	The transaction also includes a contingent consideration arrangement which may require the Company to pay the former shareholders of Immunologix 50% of revenue generated from Immunologix’s antibody technology in a specific target defined in the agreement up to a maximum of $2,000. The potential undiscounted amount of all future payments that could be required under the contingent consideration arrangement is between $0 and $2,000. No value was assigned to the contingent consideration arrangement on the acquisition date based on the risk-adjusted valuation performed by the Company. There have been no changes to the Company’s valuation of this contingent consideration as of December 31, 2013 and 2012.
	The fair value of the total consideration transferred was $13,850. The acquisition date fair value of each class of consideration transferred was as follows:
	Cash	$	12,758
	Common shares		1,092
		$	13,850
	The fair value of the shares of the Company’s common stock issued was based upon the value of the Company’s common stock at acquisition date determined by using a probability-weighted expected return method (“PWERM”) as prescribed by the AICPA Practice Aid. The PWERM estimates the value of an enterprise’s common stock based upon an analysis of current and future values for the enterprise assuming possible liquidity events. The PWERM considers the various terms of the Company’s redeemable convertible preferred stock, including the rights for each share class, at the date in the future upon which these rights will either be executed or abandoned. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	19
	Other receivables		1
	Prepaid expenses and other		6
	Property and equipment		141
	Intangible assets		13,921
	Total assets acquired		14,088
	Accounts payable		87
	Accrued compensation and benefits		76
	Capital lease obligations		75
	Total liabilities assumed		238
	Net assets acquired	$	13,850
	The fair value of acquired intangible assets was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to the intangible asset. The acquired intangible assets are being amortized over the expected useful life of thirteen years and consist of acquired patents and related technology.
	The Company paid $293 of acquisition related costs, which are included in general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2011.
Other 2011 Acquisition
In April 2011, the Company acquired certain tangible and intangible assets that were considered a business in accordance with ASC 805, Business Combinations (“ASC 805”), from a private California company for consideration of $1,400, including $850 cash and 92,984 shares of the Company’s common stock valued at $550. The acquired intangible assets, which consist of acquired patents and related technology, are being amortized over the expected useful life of thirteen years.
Unaudited Condensed Pro Forma Financial Information
The results of operations of the mergers and acquisitions discussed above are included in the consolidated statements of operations beginning on their respective acquisition dates. The following unaudited condensed pro forma financial information for the year ended December 31, 2011 is presented as if the acquisitions had been consummated on January 1, 2011:
(Unaudited)	2011
	Pro forma
Revenues	$	9,146
Net loss		(89,116	)
Accretion of dividends on redeemable convertible preferred stock, not declared		(13,868	)
Net loss attributable to common shareholders	$	(102,984	)
Net loss attributable to common shareholders per share, basic and diluted	$	(19.01	)
BioPop Acquisition
On October 1, 2013, the Company paid $1,300 to acquire 51% of the outstanding common stock of BioPop, and effective on that date, the Company began consolidating BioPop in its consolidated results of operations and financial position pursuant to ASC 805. In connection with the transaction, the Company recorded goodwill of $822 and intangible assets of $430. The intangible assets consist of acquired technology and are being amortized over the expected useful life of four years.
AquaBounty	'
Mergers and Acquisitions	'
	7. Investment in AquaBounty
	On November 16, 2012, the Company acquired 48,631,444 shares of AquaBounty common stock, representing 47.56% of the then outstanding shares of AquaBounty, for $6,000 through a definitive purchase agreement with an existing AquaBounty shareholder and its affiliate. The carrying amount of the investment in AquaBounty was $5,726 at December 31, 2012. Based on closing quoted market prices (Level 1), the fair value of the investment in AquaBounty was approximately $14,300 at December 31, 2012. Summarized unaudited financial information for AquaBounty as of December 31, 2012 and for the period from November 16, 2012 to December 31, 2012 is as follows:
		2012
	Current assets	$	514
	Non-current assets		1,962
	Total assets		2,476
	Current liabilities		706
	Non-current liabilities		2,741
	Total liabilities		3,447
	Net liabilities	$	(971	)
		2012
	Revenues	$	—
	Operating expenses		578
	Loss from operations		(578	)
	Other expense		(1	)
	Net loss	$	(579	)
	On November 29, 2012, the Company executed a promissory note purchase agreement (“promissory note”) with AquaBounty. The promissory note allowed for the Company to loan up to $500 to AquaBounty. Draws on the promissory note by AquaBounty accrued annual interest of 3% and matured no later than May 28, 2013. As of December 31, 2012, AquaBounty had drawn $200 on the promissory note. This outstanding balance plus accrued interest is included in related party receivables on the December 31, 2012 consolidated balance sheet. In January and February 2013, AquaBounty borrowed additional installments of $200 and $100, respectively, on the promissory note. On March 15, 2013, AquaBounty repaid the $500 promissory note plus accrued interest.
	On March 15, 2013, the Company acquired 18,714,814 shares of AquaBounty for $4,907 in a private subscription offering, thereby increasing the Company’s ownership in AquaBounty to 53.82%, resulting in the Company consolidating AquaBounty. Commencing on that date, AquaBounty is included in the consolidated results of operations and financial position pursuant to the step acquisition guidance in ASC 805, Business Combinations. The Company recognized a gain of $7,415 to account for the difference between the carrying value and the fair value of the previously held 47.56% equity interest. The fair value of the consideration transferred included:
	Consideration paid	$	4,907
	Fair value of noncontrolling interest		15,153
	Fair value of the Company’s investment in affiliate held before the business combination		12,751
	Fair value of the consideration transferred	$	32,811
	The Company used the private subscription price to measure fair value of the Company’s previously held investment and noncontrolling interest. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments were due to the completed valuation of intangible assets and long-term debt.
		Initial estimated fair			Adjustments			Adjusted fair value
		value
	Cash	$	5,419		$			$	5,419
	Short-term investments		14			—			14
	Trade receivables		4			—			4
	Other receivables		9			—			9
	Prepaid expenses and other		200			—			200
	Property, plant and equipment		1,241			—			1,241
	Intangible assets		14,900			—			14,900
	Other assets		22			—			22
	Total assets acquired		21,809			—			21,809
	Accounts payable		156			—			156
	Accrued compensation		94			—			94
	Other accrued liabilities		395			—			395
	Long-term debt		2,199			(845	)		1,354
	Total liabilities assumed		2,844			(845	)		1,999
	Net assets acquired		18,965			845			19,810
	Goodwill		13,846			(845	)		13,001
	Total consideration	$	32,811		$	—		$	32,811
	The fair value of acquired intangible assets was determined using the multi-period excess earnings method, a variation of the income approach that estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to the intangible asset. The acquired intangible assets consist of in-process research and development until regulatory approval is obtained, at which point the intangible assets will be accounted for as definite lived intangible assets and amortized over the expected useful life of fifteen years. The goodwill consists of future revenue opportunities and the potential for expansion of AquaBounty products. The goodwill is not expected to be deductible for tax purposes.
	The results of operations of AquaBounty are included in the consolidated statement of operations beginning on the acquisition date. The following unaudited condensed pro forma financial information for the years ended December 31, 2013 and 2012, is presented as if the acquisition had been consummated on January 1, 2012:
		Year ended December 31,
		2013			2012
		Pro forma
	Revenues	$	23,760		$	13,774
	Net loss		(48,760	)		(78,651	)
	Net loss attributable to noncontrolling interest		2,310			2,062
	Net loss attributable to Intrexon		(46,450	)		(76,589	)
	Accretion of dividends on redeemable convertible preferred stock		(18,391	)		(21,994	)
	Net loss attributable to Intrexon common shareholders	$	(64,841	)	$	(98,583	)
	Net loss attributable to Intrexon common shareholders per share, basic and diluted	$	(1.58	)	$	(17.81	)
	The pro forma net loss for the year ended December 31, 2013 excludes the $7,415 non-recurring gain on remeasurement of the Company’s previously held investment in AquaBounty. The pro forma net loss for the year ended December 31, 2012 includes this non-recurring gain on remeasurement.
	See Note 4 for discussion of the Company’s ECC with AquaBounty.

Collaboration_Revenue

Collaboration Revenue	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Collaboration Revenue	'
	4. Collaboration Revenue
	The Company’s collaborations provide for multiple deliverables to be delivered by the Company, including a license to the Company’s technology platforms, participation in collaboration committees, performance of certain research and development services and may include obligations for certain manufacturing services. The Company groups these deliverables into two units of accounting based on the nature of the deliverables and the separation criteria. The first deliverable (“Unit of Accounting 1”) includes the license to the Company’s technology platform, the Company’s participation on the collaboration committees and any research and development services associated with its technology platforms. The deliverables for Unit of Accounting 1 are combined because they cannot be individually separated. The second deliverable, (“Unit of Accounting 2”) includes manufacturing services to be provided for any Company materials in an approved product. These services have standalone value and are contingent due to uncertainties on whether an approved product will ever be developed thereby requiring manufacture by the Company at that time. As VSOE and third party evidence of selling price is not available or practical, the BESP for each unit of accounting is determined using a historical cost approach due to the early stage of development of the Company’s technology. In establishing BESP for Unit of Accounting 1, the Company uses the accumulated costs incurred as of the collaboration by the Company on its technology platform licensed to the collaborator to approximate the cost to recreate the deliverables included in this unit of accounting. All upfront consideration is allocated to Unit of Accounting 1. Unit of Accounting 2 is determined to be a contingent deliverable at the inception of the collaboration due to the uncertainties surrounding whether an approved product will ever be developed and require manufacturing by the Company. The upfront consideration allocated to Unit of Accounting 1 is recognized over the expected life of the Company’s technology platform using a straight-line approach.
	The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed and collection is reasonably assured. At the inception of each collaboration, the Company determines whether any milestone payments are substantive and can be recognized when earned in accordance with ASU 2010-17. The milestone payments are typically not considered substantive. Royalties related to product sales will be recognized when earned since payments relate directly to products that have been fully developed and for which the Company has satisfied all of its obligations.
	The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration for the years ended December 31, 2013, 2012 and 2011.
		Year ended December 31, 2013
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	2,577	$	7,818	$	10,395
	Synthetic Biologics, Inc.		2,187		1,048		3,235
	Oragenics, Inc.		673		1,517		2,190
	Fibrocell Science, Inc.		970		3,736		4,706
	Genopaver, LLC		204		935		1,139
	S & I Ophthalmic, LLC		—		417		417
	Other		333		1,110		1,443
	Total	$	6,944	$	16,581	$	23,525
		Year ended December 31, 2012
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	5,068	$	6,333	$	11,401
	Synthetic Biologics, Inc.		293		327		620
	Oragenics, Inc.		320		516		836
	Fibrocell Science, Inc.		158		61		219
	Other		12		618		630
	Total	$	5,851	$	7,855	$	13,706
		Year ended December 31, 2011
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	2,372	$	2,724	$	5,096
	Synthetic Biologics, Inc.		22		—		22
	Total	$	2,394	$	2,724	$	5,118
	The following is a summary of the terms of the Company’s significant collaborations.
	Ziopharm Collaboration
	Effective January 6, 2011, the Company entered into a worldwide ECC with Ziopharm. Pursuant to the ECC, Ziopharm received a license to the Company’s technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of Ziopharm’s common stock valued at $17,457 as upfront consideration. In addition to the deliverables discussed above, the Company transferred two clinical product candidates to Ziopharm that resulted in a separate unit of accounting for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to Unit of Accounting 1 discussed above. The Company is entitled to additional shares of common stock representing the lesser of (i) the original shares received or (ii) the number of shares representing 7.495% of Ziopharm’s outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by Ziopharm using the Company’s technology (“Ziopharm Milestone”). On October 24, 2012, the Ziopharm Milestone was achieved and the Company received 3,636,926 shares of Ziopharm’s common stock valued at $18,330 as milestone consideration. Since the Ziopharm Milestone was not substantive, the Company allocated the Ziopharm Milestone to the applicable units of accounting and is being recognized in a manner similar to these units of accounting. The Company receives reimbursement payments for research and development services provided and manufacturing services for Company materials provided to Ziopharm during the ECC. Subject to certain expense allocations, Ziopharm will pay the Company 50% of the quarterly net profits derived from the sale of products developed from the ECC. Ziopharm is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of product candidates. The term of the ECC commenced on January 6, 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Ziopharm upon 90 days written notice to the Company provided that no voluntary termination by Ziopharm can be made during the first two years of the ECC. See Note 15 for additional transactions with Ziopharm.
	On March 21, 2012, the Company received $10,000 from Ziopharm as a prepayment of research and development services to be provided in conjunction with the ECC. The Company recorded this amount as deferred revenue and recognized collaboration revenue as services were performed.
	Synthetic Biologics, Inc. Collaborations
	Effective November 18, 2011, the Company entered into a worldwide ECC with Synthetic Biologics, Inc. (“Synthetic Biologics”), a publicly traded company focused on the development of innovative disease-modifying medicines for serious illnesses. Pursuant to the ECC, at the transaction effective date, Synthetic Biologics received a license to the Company’s technology platform within a designated field (“Field One”). Upon execution of the ECC, the Company received 3,123,558 shares of Synthetic Biologics’ common stock valued at $1,687 as upfront consideration. The Company is entitled to additional shares of common stock representing the lesser of (i) the original shares received or (ii) the number of shares representing 9.995% of Synthetic Biologics’ outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by Synthetic Biologics using the Company’s technology. The Company will receive reimbursement payments for research and development services provided pursuant to the agreement and manufacturing services for Company materials provided to Synthetic Biologics during the ECC. Subject to certain expense allocations, Synthetic Biologics will pay the Company 50% of the quarterly net profits derived from the sale of products developed from the ECC. Synthetic Biologics is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced on November 18, 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Synthetic Biologics upon 90 days written notice to the Company provided that no voluntary termination by Synthetic Biologics can be made during the first 18 months of the ECC. On April 16, 2013, the Company terminated its ECC with Synthetic Biologics in Field One. As a result of this termination, all licenses granted by the Company under the ECC for use in Field One reverted back to the Company and the Company recognized the balance of deferred revenue associated with the upfront consideration as collaboration revenue in April 2013.
	On August 6, 2012, the Company entered into its second worldwide ECC with Synthetic Biologics. Pursuant to this ECC, at the transaction effective date, Synthetic Biologics received a license to the Company’s technology platform within a second designated field (“Field Two”). Upon Synthetic Biologics’ shareholders’ approval on October 5, 2012, the Company received a technology access fee of 3,552,210 shares of Synthetic Biologics common stock valued at $7,815 as upfront consideration. Upon the filing by Synthetic Biologics of an investigational new drug application with the U.S. Food and Drug Administration, or FDA, the Company will receive cash or common stock at the option of Synthetic Biologics valued at $2,000. Upon the first to occur of either the first commercial sale of a product developed under the ECC or the granting of regulatory approval of a product developed under the ECC, the Company will receive cash or common stock at the option of Synthetic Biologics valued at $3,000. The ECC initially targets three infectious diseases and Synthetic Biologics may elect to target up to five more infectious diseases by paying the Company a field expansion fee of $2,000 in either cash or common stock for each additional infectious disease selected. The Company receives reimbursement payments for research and development services provided pursuant to the agreement and manufacturing services for preclinical Company materials provided to Synthetic Biologics during the ECC. The Company has the option to propose, and Synthetic Biologics can select, the Company to be the bulk manufacturer of products developed from the ECC. On a quarterly basis, Synthetic Biologics will pay the Company royalties with percentages ranging from upper-single digits to lower double digits of net sales of products developed from the ECC. Synthetic Biologics is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced on August 6, 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Synthetic Biologics upon 90 days written notice to the Company provided that no voluntary termination by Synthetic Biologics can be made during the first 18 months of the ECC.
	On December 17, 2012, the Company received $2,500 from Synthetic Biologics as a prepayment of research and development services to be provided in conjunction with either of the two ECCs. The Company recorded this amount as deferred revenue and recognizes collaboration revenue as services are performed. Any remaining balance of this prepayment is refundable to Synthetic Biologics in the event both ECCs are terminated.
	See Note 15 for further discussion related to Synthetic Biologics.
	Oragenics Collaborations
	Effective June 5, 2012, the Company entered into a worldwide ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company’s technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of 4,392,425 shares of Oragenics’ common stock valued at $6,588 as upfront consideration. The Company is entitled to receive additional shares of common stock, or at Oragenics’ option, receive a cash payment based upon the fair market value of the shares, upon the separate achievement of certain regulatory milestones of the first product candidate developed from the ECC (“Oragenics ECC 1 Milestones”). The Oragenics ECC 1 Milestones include: (i) 1% of Oragenics’ outstanding shares as defined in the ECC agreement at the date of the filing of the first Investigative New Drug Application with the U.S. Food and Drug Administration (“U.S. FDA”) for a product candidate created, produced or developed using the Company’s technology (“Oragenics ECC 1 Product”); (ii) 1.5% of Oragenics’ outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase II clinical trial of an Oragenics ECC 1 Product; (iii) 2% of Oragenics’ outstanding shares as defined in the ECC agreement at the date of the dosing of the first patient in the first Phase III clinical trial of an Oragenics ECC 1 Product; (iv) 2.5% of Oragenics’ outstanding shares as defined in the ECC agreement at the date of the first New Drug Application or Biologics License Application with the U.S. FDA for an Oragenics ECC 1 Product, or alternatively the first equivalent regulatory filing with a foreign agency; and (v) 3% of Oragenics’ outstanding shares as defined in the ECC agreement at the date of the granting of the first regulatory approval of an Oragenics ECC 1 Product. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company 25% of the quarterly profits derived from the sale of products developed from the ECC.
	Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced on June 5, 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company provided that no voluntary termination by Oragenics can be made during the first 18 months of the ECC. See Note 15 for additional arrangements with Oragenics.
	Effective September 30, 2013, the Company entered into its second worldwide ECC with Oragenics (“ECC 2”). Pursuant to ECC 2, at the transaction effective date, Oragenics received a license to the Company’s technology platform to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus as defined more specifically in the agreement. Upon execution of ECC 2, the Company received a technology access fee of 1,348,000 shares of Oragenics’ common stock valued at $3,503 and a $1,956 convertible promissory note maturing on or before December 31, 2013 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics’ common stock subject to its shareholders’ approval. The conversion price is equal to the closing price of Oragenics’ common stock on the last trading day immediately prior to the date of conversion. On December 18, 2013, Oragenics converted the promissory note into 698,241 shares of Oragenics’ common stock. The Company is entitled to receive additional shares of common stock, or at Oragenics’ option, receive a cash payment based upon the fair market value of the shares, upon the first instance of attainment of certain commercialization milestones of a product candidate developed from ECC 2 (“Oragenics ECC 2 Milestones”). The Oragenics ECC 2 Milestones include: (i) $2,000 within thirty days of the first instance of the achievement of the first dosing of a patient in a phase II clinical trial for an Oragenics product developed from ECC 2 (“Oragenics ECC 2 Product”); (ii) $5,000 within thirty days of the first instance of the achievement of the meeting of the primary endpoint in a phase III clinical trial for an Oragenics ECC 2 Product; and (iii) $10,000 within thirty days of the first instance of the achievement of the first to occur of (a) the first commercial sale of an Oragenics ECC 2 Product anywhere in the world, or (b) the regulatory approval for an Oragenics ECC 2 Product. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during ECC 2. Oragenics will pay the Company 10% of the net sales derived from the sale of products developed from ECC 2.
	Oragenics is responsible for funding the further development of probiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of ECC 2 commenced on September 30, 2013 and continues until terminated pursuant to ECC 2. ECC 2 may be terminated by either party in the event of certain material breaches defined in the agreement and following full payment of the technology access fee may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.
	Fibrocell Science, Inc. Collaboration
	Effective October 5, 2012, the Company entered into an ECC with Fibrocell Science, Inc. (“Fibrocell”), a publicly traded, autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company’s technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of the ECC, the Company received a technology access fee of 1,317,520 shares of Fibrocell’s common stock valued at $7,576 as upfront consideration. The number of shares received reflects a 1-for-25 reverse stock split of Fibrocell’s common stock effective April 30, 2013. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from the ECC. If Fibrocell uses the Company’s technology platform to improve the production of a current or new Fibrocell products not developed from the ECC, Fibrocell will pay the Company a quarterly royalty equal to 33% of the cost of goods sold savings generated by the improvement. Fibrocell is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced on October 5, 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.
	Effective June 28, 2013, the Company entered into an amendment to the ECC with Fibrocell. The amendment expands the field of use defined in the ECC agreement. Under the terms of the amendment to the ECC, the Company received 1,243,781 shares of Fibrocell’s common stock valued at $7,612 as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting and is recognizing it consistent with the unit of accounting.
	See Note 15 for further discussion related to Fibrocell.
	Genopaver Collaboration
	Effective March 29, 2013, the Company entered into a worldwide ECC with Genopaver, a limited liability company formed by affiliates of Third Security, LLC (Note 15). Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of $3,000 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company a royalty as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced on March 29, 2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon 90 days written notice to the Company.
	AquaBounty Collaboration
	On February 14, 2013, the Company entered into an ECC with AquaBounty. The Company will be reimbursed for research and development services as provided for in the ECC agreement. In the event of product sales from a product developed from the ECC, the Company will receive 16.66% of quarterly gross profits for each product. All revenues and expenses related to this ECC are eliminated in consolidation (Note 7).
	S & I Ophthalmic Collaboration
	On September 30, 2013, the Company entered into a worldwide ECC with S & I Ophthalmic, a joint venture between the Company and Sun Pharmaceutical Subsidiary (Note 8). The ECC grants S & I Ophthalmic an exclusive worldwide license to the Company’s technology platform to develop and commercialize therapies in humans for the treatment of ocular diseases defined more specifically in the agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. Subject to certain expense allocations, S & I Ophthalmic will pay the Company royalties with percentages ranging from mid-single digits and above of the net sales derived from the sale of products developed under the ECC.
	BioPop Collaboration
	On October 1, 2013, the Company entered into a worldwide ECC with BioPop. The ECC grants BioPop an exclusive, worldwide license to the Company’s technology platform to develop and commercialize artwork, children’s toys and novelty goods that are derived from living organisms or are enabled by synthetic biology. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The Company is entitled to royalties in the mid-single digits as a percentage of the net product sales of a product developed under the ECC. All revenues and expenses related to this ECC are eliminated in consolidation (Note 3).
	OvaXon Collaboration
On December 18, 2013, the Company entered into a worldwide ECC with OvaXon, the joint venture between the Company and OvaScience (Note 8). The ECC grants OvaXon an exclusive, worldwide license to the Company’s technology platform to create new applications for improving human and animal health. OvaScience also licensed certain technology to OvaXon pursuant to a separate license agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement.
Deferred Revenue
Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company’s collaborations and prepayments for research and development services performed for collaborators pursuant to the terms of the collaborations. Deferred revenue consists of the following:
	December 31,
	2013		2012
Upfront and milestone payments	$	72,207	$	51,359
Prepaid research and development services		1,319		7,229
Other		45		48
Total	$	73,571	$	58,636
Current portion of deferred revenue		7,793		9,963
Long-term portion of deferred revenue		65,778		48,673
Total	$	73,571	$	58,636

Shortterm_and_Longterm_Investm

Short-term and Long-term Investments	12 Months Ended
	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Short-term and Long-term Investments	'
	5. Short-term and Long-term Investments
	The Company’s investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2013:
		Amortized		Gross		Gross			Aggregate
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	U.S. government debt securities	$	178,277	$	35	$	(13	)	$	178,299
	Commercial paper		7,997		—		—			7,997
	Certificates of deposit		2,266		—		(1	)		2,265
	Total	$	188,540	$	35	$	(14	)	$	188,561
	For more information on the Company’s method for determining the fair value of its assets, see Note 2 – “Fair Value of Financial Instruments”.
	The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2013 was:
	Due within one year	$	127,980
	After one year through two years		60,581
	Total	$	188,561
	Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. As of December 31, 2013, the Company had unrealized losses of $14 related to investments that had a fair value of $80,176. The unrealized losses of the Company’s investments were primarily the result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and have been in a loss position for less than 12 months.
	As of December 31, 2013 and 2012, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company’s ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	6. Fair Value Measurements
	The carrying amount of cash and cash equivalents, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.
	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2013:
		Quoted		Significant		Significant		December 31,
		prices		other		unobservable		2013
		in active		observable		inputs
		markets		inputs		(level 3)
		(level 1)		(level 2)
	Assets
	U.S. government debt securities (Note 5)	$	—	$	178,299	$	—	$	178,299
	Commercial paper (Note 5)		—		7,997		—		7,997
	Certificates of deposit (Note 5)		—		2,265		—		2,265
	Equity securities (Note 4)		110,297		31,228		—		141,525
		$	110,297	$	219,789	$	—	$	330,086
	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2012:
		Quoted		Significant		Significant		December 31,
		prices		other		unobservable		2012
		in active		observable		inputs
		markets		inputs		(level 3)
		(level 1)		(level 2)
	Assets
	Certificates of deposit (Note 5)	$	—	$	260	$	—	$	260
	Equity securities (Note 4)		72,988		10,128		—		83,116
		$	72,988	$	10,388	$	—	$	83,376
	Financial liabilities measured on a recurring basis were not significant at December 31, 2013 and 2012.
	The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quote prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability.
	There were no transfers between levels of the fair value hierarchy in the years ended December 31, 2013 and 2012.

Investments_in_Joint_Ventures

Investments in Joint Ventures	12 Months Ended
	Dec. 31, 2013
Equity Method Investments And Joint Ventures [Abstract]	'
Investments in Joint Ventures	'
	8. Investments in Joint Ventures
	S & I Ophthalmic
	On September 30, 2013, the Company and Sun Pharmaceutical Subsidiary entered into a Limited Liability Company Agreement (“Sun LLC Agreement”) which governs the affairs and the conduct of business of S & I Ophthalmic, a joint venture to develop therapies for the treatment of ocular diseases. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. In cases in which the board of managers of S & I Ophthalmic (“S & I Board”) determines that additional capital contributions are necessary in order for S & I Ophthalmic to conduct business and comply with its obligations under the ECC (Note 4), each of the Company and Sun Pharmaceutical Subsidiary have committed to making additional capital contributions to S&I Ophthalmic subject to certain limits defined in the agreement. Each has the right, but not the obligation, to make additional capital contributions above the defined limits when and if solicited by the S & I Board.
	Beginning on the seventh anniversary of the effective date of the Sun LLC Agreement, and upon the second anniversary thereafter, the Company, as well as Sun Pharmaceutical Subsidiary, may make a cash offer to purchase all of the other party’s interest in S & I Ophthalmic. Upon receipt of such an offer, the other party must either agree to tender its interests at the offered price or submit a counteroffer at a price higher than the original offer. Such offer and counteroffer may continue until one party agrees to the other’s price.
	S & I Ophthalmic is governed by the S & I Board which has four members. The Company, as well as Sun Pharmaceutical Subsidiary, has the initial right to appoint two members to the S & I Board. For so long as Sun Pharmaceutical Subsidiary and/or any of its affiliates is a member of S & I Ophthalmic and holds a percentage interest in S & I Ophthalmic that is at least equal to the percentage held by the Company and/or its affiliates, Sun Pharmaceutical Subsidiary will have the sole authority to select and appoint on behalf of S & I Ophthalmic each of the representatives of the S & I Ophthalmic on the ECC committees, and one such appointee will be an “Empowered Representative” of the S & I Ophthalmic under the terms of the ECC with final authority to resolve certain ECC committee disputes.
	As of December 31, 2013, S & I Ophthalmic has total assets and liabilities of $9,850 and $283, respectively, and incurred a net loss of $433 for the year ended December 31, 2013. The Company’s investment in S & I Ophthalmic is $4,784 as of December 31, 2013.
	OvaXon
	On December 18, 2013, the Company and OvaScience entered into a Limited Liability Company Agreement (“OvaXon LLC Agreement”) which governs the affairs and conduct of business of OvaXon, a joint venture to create new applications for improving human and animal health. OvaXon leverages experience and technology from both the Company and OvaScience. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. In cases in which the board of managers of OvaXon (“OvaXon Board”) determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations under the ECC (Note 4), each of the Company and OvaScience have the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement.
	OvaXon is governed by the OvaXon Board which has four members. The Company, as well as OvaScience, has the initial right to appoint two members to the OvaXon Board. For so long as OvaScience and/or any of its affiliates is a member of OvaXon and holds at least 25% interest in OvaXon, OvaScience will have the sole authority to select and appoint on behalf of OvaXon each of the representatives of OvaXon on the ECC committees, and one such appointee will be an “Executive Officer” of OvaXon under the terms of the ECC with final authority to resolve certain ECC committee disputes.

Property_Plant_and_Equipment_n

Property, Plant and Equipment, net	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment, net	'
	9. Property, Plant and Equipment, net
	Property, plant and equipment consist of the following:
		December 31,
		2013			2012
	Land	$	55		$	—
	Building		945			—
	Furniture and fixtures		876			857
	Lab equipment		22,275			22,195
	Leasehold improvements		5,147			4,972
	Computer hardware		3,286			3,136
	Construction in progress		314			14
	Software		1,008			888
			33,906			32,062
	Less: Accumulated depreciation and amortization		(17,277	)		(13,375	)
	Property, plant and equipment, net	$	16,629		$	18,687
	Depreciation expense was $4,325, $4,957 and $3,078 for the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company leases certain property and equipment which are classified as capital leases. The net book value of this property and equipment was insignificant as of December 31, 2013 and 2012.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, net	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets, net	'
	10. Goodwill and Intangible Assets, net
	The changes in the carrying amount of goodwill for the year ended December 31, 2013 are as follows:
	Balance as of December 31, 2012	$	—
	Acquisitions		13,823
	Balance as of December 31, 2013	$	13,823
	No goodwill or accumulated impairment losses existed as of December 31, 2013.
	Intangible assets consist of the following at December 31, 2013:
		Gross Carrying		Accumulated			Net
		Amount		Amortization
	Patents and related technologies	$	34,772	$	(7,716	)	$	27,056
	In-process research and development		14,900		—			14,900
	Total	$	49,672	$	(7,716	)	$	41,956
	No in-process research and development or accumulated impairment losses existed as of December 31, 2013.
	Intangible assets consist of the following at December 31, 2012:
		Gross Carrying		Accumulated			Net
		Amount		Amortization
	Patents and related technologies	$	34,342	$	(4,851	)	$	29,491
	Favorable rent asset		646		(631	)		15
	Total	$	34,988	$	(5,482	)	$	29,506
	Amortization expense was $2,880, $3,027 and $1,260 for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2013, the weighted average useful life for patents and related technology was 12.3 years. Total amortization expense is estimated to be $2,748 for each year from 2014 through 2015, $2,749 for 2016, $2,721 for 2017, $2,641 for 2018, and $13,449 for the cumulative period thereafter.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	11. Income Taxes
	For the year ended December 31, 2013, domestic loss before income taxes total $39,250, while foreign loss before income taxes total $1,658. For the years ended December 31, 2012 and 2011, loss before income taxes was solely domestic. There is no income tax benefit recognized for the years ended December 31, 2013, 2012 and 2011 due to the Company’s and its subsidiaries’ histories of net losses combined with an inability to confirm recovery of the tax benefits of the Company’s and its subsidiaries’ losses and other net deferred tax assets. Income tax benefit for the years ended December 31, 2013, 2012 and 2011 differed from amounts computed by applying the applicable U.S. federal corporate income tax rate of 34% to loss before income taxes as a result of the following:
		2013			2012			2011
	Computed statutory income tax benefit	$	(13,909	)	$	(27,837	)	$	(28,995	)
	(Increase) reduction in income tax benefit resulting from State income tax benefit, net of federal income taxes		(1,834	)		(3,711	)		(3,893	)
	Nondeductible stock based compensation		575			333			203
	Contribution of services by shareholder		527			527			71
	Gain in previously held equity investment		(2,477	)		—			—
	Research and development tax credits		(1,203	)		—			(2,515	)
	Other, net		1,317			(238	)		477
			(17,004	)		(30,926	)		(34,652	)
	Change in valuation allowance for deferred tax assets		17,004			30,926			34,652
	Total income tax provision	$	—		$	—		$	—
	The tax effects of temporary differences that comprise the deferred tax assets and liabilities at December 31 are as follows:
		2013			2012
	Deferred tax assets
	Equity securities	$	415		$	4,346
	Accrued liabilities		1,445			1,910
	Stock-based compensation		1,677			363
	Deferred revenue		28,456			22,684
	Research and development tax credits		10,062			5,848
	Net operating loss carryforwards		97,395			80,159
	Total deferred tax assets		139,450			115,310
	Less: Valuation allowance		131,985			113,051
	Net deferred tax assets		7,465			2,259
	Deferred tax liabilities
	Property and equipment		140			478
	Intangible assets		7,325			1,781
	Total deferred tax liabilities		7,465			2,259
	Net deferred tax assets (liabilities)	$	—		$	—
	Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2013, 2012 and 2011 was as follows:
		2013			2012			2011
	Valuation allowance at beginning of year	$	113,051		$	82,125		$	52,036
	(Decrease) increase in valuation allowance as a result of
	Mergers and acquisitions, net		1,930			—			(4,563	)
	Current year operations		17,004			30,926			34,652
	Valuation allowance at end of year	$	131,985		$	113,051		$	82,125
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries’ histories of net losses incurred from inception, no income tax benefit has been recorded and the corresponding deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized in accordance with the provisions of ASC 740. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.
	The American Taxpayer Relief Act of 2012, which retroactively reinstated the federal research and development tax credit for 2012, was not enacted into law until January 2013. Therefore, the deferred tax asset and corresponding increase in the valuation allowance for the amount of the tax credit generated in 2012 are reflected in 2013 for financial statement purposes.
	The Company’s past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986. As a result, utilization of portions of the net operating losses may be subject to annual limitations. As of December 31, 2013, approximately $16,400 of the Company’s net operating losses generated prior to 2008 are limited by Section 382 to annual usage limits of approximately $1,500. As of December 31, 2013, approximately $14,800 of the Company’s net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction.
	At December 31, 2013, the Company has loss carryforwards for federal income tax purposes of approximately $242,318 available to offset future taxable income and federal and state research and development tax credits of $6,968, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. Of these loss carryforwards, $2,636 relate to benefits from stock compensation deductions that will be recorded as a component of paid-in capital when realized.
	The Company does not file a consolidated income tax return with AquaBounty or BioPop. At December 31, 2013, AquaBounty has loss carryforwards for federal and foreign income tax purposes of approximately $8,300 and $4,100, respectively, available to offset future taxable income and foreign research and development tax credits of $3,000, prior to consideration of annual limitations that may be imposed under Section 382 or analogous foreign provisions. These carryforwards will begin to expire in 2019. As a result of the Company’s ownership in AquaBounty passing 50% in 2013, an annual Section 382 of approximately $900 per year will apply to losses and credits carried forward by AquaBounty from prior years, which are also subject to prior Section 382 limitations. At December 31, 2013, BioPop had an insignificant amount of loss carryforwards for federal income tax purposes available to offset future taxable income.
	The Company and its subsidiaries apply provisions related to the accounting for uncertain income tax positions in ASC 740-10. The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2013. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company’s tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating losses and research and development tax credits.

Redeemable_Convertible_Preferr

Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit)	'
	12. Redeemable Convertible Preferred Stock and Shareholders’ Equity (Deficit)
	The tables below represent a rollforward of the Redeemable Convertible Preferred Stock:
		Series A						Series B						Series B-1
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		705,400		$	802			694,000		$	639			1,212,360		$	1,300
	Accretion of dividends		—			556			—			30			—			60
	Balances at December 31, 2012		705,400			1,358			694,000			669			1,212,360			1,360
	Accretion of dividends		—			52			—			19			—			37
	Conversion to common stock		(705,400	)		(1,410	)		(694,000	)		(688	)		(1,212,360	)		(1,397	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series C						Series C-1						Series C-2
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		4,546,360		$	6,729			15,934,528		$	32,264			18,617,020		$	41,987
	Accretion of dividends		—			405			—			1,937			—			2,525
	Balances at December 31, 2012		4,546,360			7,134			15,934,528			34,201			18,617,020			44,512
	Accretion of dividends		—			266			—			1,272			—			1,660
	Conversion to common stock		(4,546,360	)		(7,400	)		(15,934,528	)		(35,473	)		(18,617,020	)		(46,172	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series C-3						Series D						Series E
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		13,297,872		$	28,082			19,803,685		$	71,924			22,285,716		$	117,954
	Issuance of shares		—			—			—			—			15,809,523			83,000
	Accretion of dividends		—			1,688			—			4,328			—			10,465
	Stock issuance costs		—			—			—			—			—			(16	)
	Balances at December 31, 2012		13,297,872			29,770			19,803,685			76,252			38,095,239			211,403
	Accretion of dividends		—			1,103			—			2,827			—			7,931
	Conversion to common stock		(13,297,872	)		(30,873	)		(19,803,685	)		(79,078	)		(38,095,239	)		(219,332	)
	Settlement of fractional shares upon conversion to common stock		—			—			—			(1	)		—			(2	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series F
		redeemable
		convertible
		preferred stock
		Shares			Amount
	Balances at December 31, 2012		—		$	—
	Issuance of shares		19,047,619			150,000
	Accretion of dividends		—			3,224
	Stock issuance costs		—			(3,148	)
	Conversion to common stock		(19,047,619	)		(150,075	)
	Settlement of fractional shares upon conversion to common stock		—			(1	)
	Balances at December 31, 2013		—		$	—
	The Series F Redeemable Convertible Preferred Stock (“Series F”), Series E Redeemable Convertible Preferred Stock (“Series E”), Series D Redeemable Convertible Preferred Stock (“Series D”), Series C-3 Redeemable Convertible Preferred Stock (“Series C-3”), Series C-2 Redeemable Convertible Preferred Stock (“Series C-2”), Series C-1 Redeemable Convertible Preferred Stock (“Series C-1”), Series C Redeemable Convertible Preferred Stock (“Series C”), Series B-1 Redeemable Convertible Preferred Stock (“Series B-1”), Series B Redeemable Convertible Preferred Stock (“Series B”) and Series A Redeemable Convertible Preferred Stock (“Series A”) collectively are referred to as the “Series Preferred”.
	Upon closing of the IPO on August 13, 2013, all Series Preferred shares, including $68,850 of accrued but unpaid dividends thereon, automatically converted into 79,705,130 shares of common stock. Prior to conversion, the Series Preferred had optional redemption provisions whereby after May 25, 2016, but prior to the occurrence of a qualified IPO, the holders of greater than three-fourths of then issued and outstanding shares of the Series F, Series E, Series D, Series C-3, Series C-2, Series C-1 and Series C, voting as a separate class, could have elected by written notice to require the Company to redeem all of the then issued and outstanding shares of Series F, Series E, Series D, Series C-3, Series C-2, Series C-1 and Series C at an amount equal to the stated price adjusted for any stock dividends, combination or splits plus all accrued but unpaid dividends. Upon receipt of such written notice, the Company must notify the holders of the Series B-1, Series B and Series A of the redemption notice, upon which the holders of each of those classes could have required the Company to redeem all of the then issued and outstanding shares of such class. As a result of this optional redemption provision, the Company accreted changes in the redemption value from the date of issuance of all Series Preferred shares with a resultant change to additional paid-in capital or accumulated deficit in the absence of additional paid-in capital. As of December 31, 2012, $50,549 of cumulative dividends had been accreted to the redemption price for Series Preferred on the Company’s consolidated balance sheet.

Stock_Option_Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Option Plans	'
	13. Stock Option Plans
	Intrexon Stock Option Plan
	The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation cost that has been included in research and development expenses and general and administrative expenses amounted to $514 and $2,298, respectively, for the year ended December 31, 2013, $377 and $1,081, respectively, for the year ended December 31, 2012, and $763 and $220, respectively, for the year ended December 31, 2011.
	On April 18, 2008, the Company adopted the 2008 Equity Incentive Plan (the “2008 Plan”) for employees and nonemployees pursuant to which the Company’s board of directors may grant share based awards, including stock options, to officers, key employees and nonemployees. During 2011, the 2008 Plan was amended to increase the number of authorized awards under the 2008 plan from 2,857,142 to 5,714,285. Awards issued pursuant to the Company’s 2004 Stock Option Plan, the 2004 Stock Option Plan for Nonemployees and the 2006 Stock Option Plan were consolidated into the 2008 Plan and are subject to, and administered under the terms of the 2008 Plan. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the “2013 Plan”), no new awards may be granted under the 2008 Plan. As of December 31, 2013, there were 2,554,648 stock options outstanding under the 2008 Plan.
	On July 26, 2013, the Company adopted the 2013 Plan for employees and nonemployees pursuant to which the Company’s board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective upon the closing of the IPO and 7,000,000 shares of common stock are reserved for issuance under the 2013 Plan. As of December 31, 2013, there were 286,000 stock options outstanding under the 2013 Plan, and there were 6,712,435 remaining shares available for the Company to grant under the 2013 Plan.
	Stock options may be granted with an exercise price equal to or greater than the stock’s fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock’s fair market value at the date of grant if the stock options are replacement options in accordance with certain U.S. Treasury regulations. Virtually all stock options have ten-year terms and vest no more than four years from the date of grant.
	The Company uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Since the Company does not have sufficient history to estimate the expected volatility of our common stock price, expected volatility is based on the average volatility of peer public entities that are similar in size and industry. The Company estimates the expected term of all options based on previous history of exercises. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as the Company has not declared any common stock dividends to date and does not expect to declare common stock dividends in the near future. Prior to the Company’s IPO, the fair value of the underlying common stock is determined based on a valuation of the Company’s common stock. Subsequent to the Company’s IPO, the fair value of the underlying common stock is determined based on the quoted market price on the NYSE. Actual forfeitures are recorded when incurred and estimated forfeitures are reviewed and adjusted at least annually. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2013, 2012 and 2011 are set forth below:
			2013		2012	2011
	Valuation assumptions
	Expected dividend yield		0%		0%	0%
	Expected volatility		73%—75%		71%—76%	68%—72%
	Expected term (years)		6.25		6	5.37— 6.23
	Risk-free interest rate		0.96%—1.86%		0.80%—1.10%	1.34%—2.51%
	Stock option activity was as follows:
			Number of			Weighted			Weighted
			shares			average			average
						exercise			remaining
						price			contractual
									term
	Balances at December 31, 2010			1,448,145		$	2.71			6.99
	Granted			2,429,684			6.48
	Exercised			(75,840	)		(2.43	)
	Forfeited			(145,214	)		(3.34	)
	Expired			(42,245	)		(2.94	)
	Balances at December 31, 2011			3,614,530			5.22			6.67
	Granted			548,571			7.12
	Exercised			(194,570	)		(2.43	)
	Forfeited			(1,210,857	)		(6.30	)
	Expired			(444,148	)		(2.29	)
	Balances at December 31, 2012			2,313,526			5.9			7.87
	Granted			989,709			13.06
	Exercised			(88,764	)		(6.04	)
	Forfeited			(335,746	)		(6.94	)
	Expired			(38,077	)		(5.17	)
	Balances at December 31, 2013			2,840,648			8.27			7.75
	Exercisable at December 31, 2013			1,227,563			5.37			6.44
	Vested and Expected to Vest at December 31, 2013(1)			2,469,860			7.8			7.57
	-1	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
	Total unrecognized compensation costs related to nonvested awards at December 31, 2013, 2012 and 2011 were $9,639, $4,910 and $6,347, respectively, and are expected to be recognized over a weighted-average period of approximately three years.
	The weighted average grant date fair value of options granted during 2013, 2012 and 2011 was $12.91, $4.60 and $4.13, respectively. The aggregate intrinsic value of options exercised during 2013, 2012 and 2011 was $1,136, $913 and $264, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of the Company’s common stock for those shares that had exercise prices lower than the fair value of the Company’s common stock.
	The following table summarizes additional information about stock options outstanding as of December 31, 2013:
	Options outstanding										Options exercisable
	Exercise price		Number of			Weighted			Aggregate		Number of		Weighted		Aggregate
			options			average			intrinsic		options		average		intrinsic
						remaining			value				remaining		value
						life (years)							life
													(years)
	$0.39			57,263			5.72		$	1,341		57,263		5.72	$	1,341
	$1.34			106,776			2.1			2,398		106,776		2.1		2,398
	$1.92			12,855			3.22			281		12,855		3.22		281
	$2.74			175,040			3.66			3,686		175,040		3.66		3,686
	$3.29			156,055			6.14			3,201		143,411		6.1		2,941
	$5.91			150,062			7.15			2,685		75,771		7.07		1,356
	$7.12			1,194,887			7.8			19,931		546,805		7.77		9,121
	$9.67			701,710			9.41			9,915		107,142		9.41		1,514
	$19.83			225,500			9.96			895		—		—		—
	$26.76			42,500			9.69			—		—		—		—
	$28.69			18,000			9.62			—		2,500		9.62		—
				2,840,648			7.75		$	44,333		1,227,563		6.44	$	22,638
	The following table summarizes additional information about stock options outstanding as of December 31, 2012:
	Options outstanding										Options exercisable
	Exercise price		Number of			Weighted			Aggregate		Number of		Weighted		Aggregate
			options			average			intrinsic		options		average		intrinsic
			remaining			value					remaining		value
			life (years)								life
											(years)
$0.39			57,263			8.07		$	385		57,263		8.07	$	385
$1.34			106,776			3.1			617		106,776		3.1		617
$1.92			23,145			4.25			120		23,145		4.25		120
$2.74			186,286			4.62			815		186,286		4.62		815
$3.29			183,442			6.77			703		126,014		6.72		483
$5.91			169,857			7.64			205		42,571		7.59		51
$7.12			1,586,757			8.77			—		266,578		8.53		—
			2,313,526			7.87		$	2,845		808,633		6.43	$	2,471
The Company currently uses authorized and unissued shares to satisfy share award exercises.
AquaBounty Stock Option Plan
The AquaBounty 2006 Equity Incentive Plan (the “AquaBounty Plan”) provides for the issuance of incentive stock options to employees of AquaBounty and non-qualified stock options and awards of restricted and direct stock purchases to its directors, officers, employees and consultants of AquaBounty. Unless otherwise indicated, options issued to employees, directors and non-employees are vested over one to three years and are exercisable for a term of ten years from the date of issuance. As of December 31, 2013, there were 6,624,000 options outstanding under the AquaBounty Plan at a weighted average exercise price of $0.25 per share of which 6,052,000 were exercisable. Stock based compensation cost for the year ended December 31, 2013 amounted to $109 and is included in general and administrative expenses.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	14. Commitments and Contingencies
	Operating Leases
	The Company leases its facilities and certain equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. At December 31, 2013, future minimum lease payments under noncancelable operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
	2014	$	3,661
	2015		3,408
	2016		2,687
	2017		1,419
	2018		72
			11,247
	Rent expense, including other facility expenses, was $5,577, $5,036 and $4,000 in 2013, 2012 and 2011, respectively.
	The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was $365, $151 and $158 for the years ended December 31, 2013, 2012 and 2011, respectively. Future rental income is $365 for 2014 and $152 for 2015.
	Capital Leases
	The Company leases certain lab equipment, computer equipment, and leasehold improvements under capital leases. At December 31, 2013, future minimum lease payments under capitalized lease obligations are insignificant.
	Long-Term Debt
	In January 2009, the Atlantic Canada Opportunities Agency (“ACOA”), a Canadian government agency, awarded AquaBounty a grant to provide funding of a research and development project. The total amount available under the award is $2,685, which AquaBounty can claim over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to regulatory approval, the timing of repayment is uncertain. As of the acquisition date, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107 (Note 7). The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Since the acquisition date and through December 31, 2013, AquaBounty has made subsequent claims of $486 resulting in total long-term debt of $1,653 as of December 31, 2013.
	In November 1999, Technology Partnership Canada (“TPC”), a Canadian government agency, agreed to provide AquaBounty funding up to $2,772, to support AquaBounty’s research and development. This amount is repayable to TPC in the form of a 5.2% royalty on revenues generated from AquaBounty’s technology through June 30, 2014. Because no amounts are likely to be required to be repaid prior to June 30, 2014, no amounts are recorded on the consolidated balance sheet as December 31, 2013.
	Contingencies
	The Company may become subject to claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2013 and 2012, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	15. Related Party Transactions
	Third Security, LLC (“Third Security”) and Affiliates
	Certain affiliates of Third Security were shareholders of the Series B, B-1, C, C-1, C-2, C-3, D, E, and F Redeemable Convertible Preferred Stock.
	On April 8, 2011, in anticipation of the closing of Series E, the Company issued convertible promissory notes with borrowings up to $25,000 to affiliates of Third Security. Terms of the notes included 12% simple interest annually with principal and interest due on or before June 30, 2011. The principal amount and all accrued interest automatically convert to shares of Series E upon the first sale of Series E. The Company borrowed $15,000 on the notes. The principal amount plus accrued interest of $165 was converted into 2,888,635 shares of Series E on May 26, 2011.
	On June 6, 2011, the Company entered into a worldwide exclusive licensing agreement with Halozyme Therapeutics, Inc. (“Halozyme”) for the use of Halozyme’s proprietary enzyme in one of the Company’s targeted therapeutics. The Company and Halozyme are related parties through common ownership by affiliates of Third Security. The Company’s CEO also serves on Halozyme’s board of directors. Under the terms of the agreement, the Company paid a license fee of $9,000 upon execution of the agreement, which is recorded in research and development expenses on the accompanying consolidated statement of operations. The Company is required to pay an annual exclusivity fee of $1,000 commencing June 6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. If the Company successfully develops a product candidate using the license in the exclusive field of use and achieves an established sales target, the Company could pay up to $54,000 in milestone payments. The Company is obligated to pay tiered royalties on net sales of the approved product. The Company may terminate this agreement in whole or on a product-by-product basis at any time upon 30 days written notice to Halozyme.
	Effective August 31, 2011, the Company entered into an asset purchase agreement with Cyntellect, Inc. (“Cyntellect”) to purchase the assets required to operate Cyntellect’s cell processing platform business and assume certain liabilities related to the assets acquired, including assumption of the remaining term on the facility lease. The Company anticipates using the assets acquired to establish the capability to develop proprietary cell lines to be used internally by the Company or with the Company’s collaborative partners. As consideration for the asset purchase, the Company issued 2,386,803 shares of its common stock valued at $17,000. Cyntellect was a related party and under common control by affiliates of Third Security. The Company recorded the transaction as a transaction between entities under common control using the guidance in ASC Subtopic 805-50, Business Combinations: Related Issues (“ASC 805-50”). ASC 805-50 requires that assets acquired and liabilities assumed be recorded on the transaction date at the carrying amount in the accounts of the transferring entity. The carrying amounts of the assets acquired and liabilities assumed is as follows:
	Cash	$	88
	Other current assets		23
	Property and equipment, net		1,724
	Other assets		262
	Total assets acquired		2,097
	Accounts payable		41
	Other accrued liabilities		107
	Long-term debt		116
	Total liabilities assumed		264
	Net assets acquired	$	1,833
	ASC 805-50 also requires that results of operations be presented as if the transaction occurred at the beginning of the period and represent the combined operations of both entities. Financial statements and financial information presented for prior years in which the entities were under common control should also be retrospectively adjusted to furnish comparative information as if the entities were combined. The Company applied these presentation requirements of ASC 805-50.
	The Company paid $128 of costs associated with this asset purchase, which are included in general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2011.
	The Manager of Third Security is also the Chief Executive Officers (“CEO”) and Chairman of the Board of the Company. The CEO has not received compensation for his services as CEO, and as a result, the Company recorded $1,550, $1,550 and $210 in compensation expense for the years ended December 31, 2013, 2012 and 2011, respectively, based on the estimated salary and benefits appropriate for the role.
	Transactions with Other Shareholders
	At December 31, 2013 and 2012, the Company leased two office facilities from an affiliate of certain shareholders. The Company has a receivable due from this affiliate in the form of security deposits which are included in other long term assets of $66 at December 31, 2013 and 2012. During 2013, 2012 and 2011, the Company incurred rent and other facility expenses of $918, $903 and $783, respectively.
	The Company contracts with a shareholder to provide certain research and clinical services. During the years ended December 31, 2013, 2012 and 2011, the Company incurred total expenses for work performed under such contract of $152, $91 and $202, respectively, none of which was payable at December 31, 2013 and 2012.
	In 2011, the Company paid a transaction fee in conjunction with the closing of its Series E to a financial services firm who employs certain shareholders of the Company.
	Transactions with ECC Parties
	On January 6, 2011, in conjunction with the ECC with Ziopharm (Note 4), the Company purchased 2,426,235 shares of common stock at $4.80 per share at closing in a private placement. The Company agreed to purchase up to an additional $50,000 of common stock in conjunction with securities offerings that may be conducted by Ziopharm in the future, subject to certain conditions and limitations. On February 7, 2011, the Company purchased 1,910,000 shares of Ziopharm common stock at $5.75 per share in the first such securities offering. On January 20, 2012, the Company purchased 1,923,075 shares of Ziopharm common stock at $5.20 per share in another securities offering. On October 29, 2013, the Company purchased 2,857,143 shares of Ziopharm common stock at $3.50 per share in a securities offering. At December 31, 2013, the Company had approximately $19,000 remaining on its purchase commitment. In conjunction with the ECC and the initial share purchase, the CEO of the Company joined the board of directors of Ziopharm.
	In conjunction with the ECC with Synthetic Biologics (Note 4), the Company is entitled to, at its election, purchase up to 19.99% of securities offerings that may be conducted by Synthetic Biologics in the future, subject to certain conditions and limitations. On December 17, 2013, the Company purchased 2,000,000 shares of Synthetic Biologics common stock at $1.00 per share in a securities offering under this right. The Company has been granted the right to make purchases of Synthetic Biologics’ common stock in the open market up to an additional 10% of Synthetic Biologics’ common stock, but has made no such purchases.
	In conjunction with the ECC with Oragenics (Note 4), the Company is entitled to, at its election, purchase up to 30% of securities offerings that may be conducted by Oragenics in the future, subject to certain conditions and limitations. On November 20, 2013, the Company purchased 1,100,000 shares of Oragenics common stock at $2.50 per share under this right. On September 30, 2013, the Company purchased 1,300,000 shares of Oragenics common stock at $3.00 per share in a private transaction.
	On October 1, 2013, the Company purchased 2,439,024 shares of Fibrocell common stock at $4.10 per share.
	In conjunction with an ECC with another collaborator, the Company is entitled to, at its election, participate in securities offerings conducted by the collaborator in the future, subject to certain conditions and limitations. The Company has made no purchases of the collaborator’s common stock.

Net_Loss_per_Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	16. Net Loss per Share
	The following table presents the historical computation of basic and diluted net loss per share:
		Year ended
		December 31,
		2013			2012			2011
	Historical net loss per share:
	Numerator:
	Net loss	$	(38,980	)	$	(81,874	)	$	(85,280	)
	Add: Accretion of dividends on redeemable convertible preferred stock		(18,391	)		(21,994	)		(13,868	)
	Net loss attributable to common shareholders		(57,371	)		(103,868	)		(99,148	)
	Denominator:
	Weighted average shares outstanding, basic and diluted		40,951,952			5,533,690			5,240,647
	Net loss attributable to common shareholders per share, basic and diluted	$	(1.40	)	$	(18.77	)	$	(18.92	)
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2013, 2012, and 2011, as they would have been anti-dilutive:
		December 31,
		2013			2012			2011
	Common shares issuable upon conversion of all Series Preferred		—			64,517,977			55,483,966
	Options		2,840,648			2,313,526			3,614,530
	Warrants		414,404			511,098			511,098
	Total		3,255,052			67,342,601			59,609,594
	In addition to the potentially dilutive securities in the table above, Series Preferred cumulative dividends convertible into common shares at a price per share equal to the fair market value of a common share at the time of conversion have been excluded from the computation of diluted weighted-average shares outstanding as of December 31, 2012 and 2011.

Quarterly_Financial_Informatio

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information (Unaudited)	'
	17. Quarterly Financial Information (Unaudited)
	The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information.
		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Total revenues	$	3,885		$	6,690		$	6,042		$	7,143
	Operating loss	$	(14,006	)	$	(14,254	)	$	(12,037	)	$	(17,726	)
	Net income (loss)	$	(36,362	)	$	(6,519	)	$	14,991		$	(13,018	)
	Net income (loss) attributable to Intrexon	$	(36,311	)	$	(5,905	)	$	15,440		$	(12,204	)
	Net income (loss) attributable to common shareholders per share, basic	$	(7.54	)	$	(2.44	)	$	0.15		$	(0.13	)
	Net income (loss) attributable to common shareholders per share, diluted	$	(7.54	)	$	(2.44	)	$	0.15		$	(0.13	)
		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Total revenues	$	1,564		$	2,716		$	2,925		$	6,569
	Operating loss	$	(25,121	)	$	(21,248	)	$	(16,485	)	$	(12,303	)
	Net loss	$	(13,912	)	$	(16,535	)	$	(20,490	)	$	(30,937	)
	Net loss attributable to common shareholders per share, basic and diluted	$	(3.55	)	$	(3.99	)	$	(4.66	)	$	(6.52	)

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2013
Postemployment Benefits [Abstract]	'
Defined Contribution Plan	'
	18. Defined Contribution Plan
	The Company sponsors a defined contribution plan covering employees who meet certain eligibility requirements. The Company makes contributions to the plan in accordance with terms specified in the plan agreement. The Company’s contributions to the plan were $598, $755 and $433 in 2013, 2012 and 2011, respectively.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	19. Subsequent Events
	The Company applies the provisions of ASC 855, Subsequent Events (“ASC 855”), which provides general standards of accounting for and disclosures of events that occur after the consolidated balance sheet date, but before consolidated financial statements are issued or are available to be issued. The Company evaluated subsequent events that occurred after December 31, 2013 up through the date the consolidated financial statements were issued.
	On March 4, 2014, the Company entered into a lease for lab operations. The lease term will begin on the later of September 1, 2014 or the date the facility is ready of occupancy and terminates approximately seven years from the lease commencement date. The Company is not required to pay rent the first six months of the lease term. Total annual rental payments, assuming a lease commencement date of November 1, 2014, are $575, $1,153, $1,188, $1,223 and $3,665 for the years ended December 31, 2015, 2016, 2017, and 2018 and period thereafter, respectively. The Company is also responsible for its pro-rata share of building operating expenses.
	On March 6, 2014, the Company acquired California-based Medistem, Inc. (“Medistem”) for approximately $24,600 in cash and Company common stock. Under the terms of the agreement, Medistem stockholders received in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of the Company’s common stock, or approximately 0.03920 shares, based on the 20-day volume-weighted average price of the Company’s common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement.
	On March 20, 2014, the Company acquired 19,040,366 additional shares of AquaBounty common stock for $10,000 in a private subscription offering, thereby increasing the Company’s aggregate ownership in AquaBounty to 59.85% upon closing.
	From January 1, 2014 through March 20, 2014, the Company granted 5,950,000 stock options from the 2013 Plan to employees and nonemployee directors. On March 20, 2014, the Company’s board of directors authorized, subject to shareholder approval, the number of shares reserved for issuance under the 2013 Plan to be increased by 3,000,000 shares.
	On March 26, 2014, the Company announced the formation of Intrexon Energy Partners, LLC (“IEP”), a joint venture between the Company and a select group of external investors, to scale-up the Company’s gas-to-liquid bioconversion platform for the production of fuels and lubricants. The Company entered into a worldwide ECC with IEP and received a technology access fee of $25,000. Additionally, the Company entered into securities purchase agreements with the external investors in IEP for the private placement of 972,004 shares of the Company’s common stock at a price per share of $25.72 for gross proceeds of $25,000.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Revenue Recognition	'
	Revenue Recognition
	The Company generates revenue through contractual agreements with collaborative partners (known as exclusive channel collaborations, “ECC” or “ECCs”) whereby the partners obtain exclusive access to the Company’s proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these collaborative agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific application provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration.
	The Company’s collaboration agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. Effective January 1, 2011, the Company adopted the provisions of Accounting Standards Update (“ASU”) No. 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements (“ASU 2009-13”). In accordance with the provisions of ASU 2009-13, the Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborative partner on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.
	Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price (“BESP”) for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations.
	The terms of the Company’s agreements may provide for milestone payments upon achievement of certain defined events. The Company applies ASU No. 2010-17, Revenue Recognition — Milestone Method (“ASU 2010-17” or “Milestone Method”). Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
	-1	The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;
	-2	The consideration relates solely to past performance; and
	-3	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
	In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.
	Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.
Research and Development	'
	Research and Development
	The Company considers that regulatory and other uncertainties inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, and the costs of consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.
	The Company has research and development arrangements with third parties that include upfront and milestone payments. At December 31, 2013 and 2012, the Company had research and development commitments with third parties totaling $2,445 and $3,164, respectively, of which $957 and $1,431, respectively, had not yet been incurred. The commitments are generally cancellable by the Company at any time upon written notice.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. At December 31, 2013 and 2012, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $43,733 and $9,384, respectively.
Short-term and Long-term Investments	'
	Short-term and Long-term Investments
	Short-term and long-term investments include U.S. government debt securities, commercial paper and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management’s reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company’s written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor’s, Moody’s and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.
Equity Securities	'
	Equity Securities
	The Company holds equity securities received and/or purchased from certain collaborative partners. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these partners. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborative partners. These equity securities are classified as noncurrent in the consolidated balance sheet as the Company does not intend to sell these equity securities within one year. The Company has not sold any of these equity securities to date.
	The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator’s security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
	Level 1		Quoted prices in active markets for identical assets and liabilities;
	Level 2		Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and
	Level 3		Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.
Concentrations of Risk	'
	Concentrations of Risk
	Due to the Company’s mix of fixed and variable rate securities holdings, the Company’s investment portfolio is susceptible to changes in interest rates. As of December 31, 2013, the Company’s investments had gross unrealized losses of $14. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.
Equity Method Investments	'
	Equity Method Investments
	Through March 15, 2013, the Company accounted for its investment in AquaBounty using the equity method of accounting since the Company had the ability to exercise significant influence, but not control, over the operating activities of AquaBounty. The excess of the investment over the Company’s pro-rata share of AquaBounty’s net assets represented identifiable intangible assets and equity-method goodwill. On March 15, 2013, the Company acquired additional ownership interests in AquaBounty which resulted in the Company gaining control over AquaBounty, thereby requiring consolidation effective on that date (Note 7).
	The Company applied the equity method of accounting to account for its investment in S & I Ophthalmic, LLC (“S & I Ophthalmic”), a joint venture between the Company and an indirect subsidiary (“Sun Pharmaceutical Subsidiary”) of Sun Pharmaceutical Industries Ltd. (“Sun Pharmaceutical”), an international specialty pharmaceutical company focused on chronic diseases. The Company also applied the equity method of accounting to its investment in OvaXon, LLC (“OvaXon”), a joint venture between the Company and OvaScience Inc. (“OvaScience”), a life sciences company focused on infertility treatments (Note 8). The Company accounts for its investments in S & I Ophthalmic and OvaXon using the equity method of accounting since the Company has the ability to exercise significant influence, but not control, over the operating activities of these entities. See Note 8 for additional discussion of S & I Ophthalmic and OvaXon.
	The Company determined that it has significant influence over two and one of its collaborators as of December 31, 2013 and 2012, respectively, based on its ownership interest, representation on the board of directors of the collaborator and other qualitative factors. As of December 31, 2012, the Company determined that one of these collaborators, Ziopharm Oncology, Inc. (“Ziopharm”), met the criteria of SEC Regulation S-X Article 3-09 for inclusion of separate financial statements of an equity method investment. The Company accounts for this investment using the fair value option. The fair value of the Company’s equity securities of Ziopharm was $71,134 and $56,298 as of December 31, 2013 and 2012, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company’s ownership interest in Ziopharm was 16.4% and 16.3% at December 31, 2013 and 2012, respectively. Unrealized appreciation (depreciation) in the fair value of the Company’s equity securities held in Ziopharm was $4,836, $(7,194), and $(4,924) for the years ended December 31, 2013, 2012 and 2011, respectively.
	In September 2013, the Company increased its investment in Oragenics, Inc. (“Oragenics”) resulting in the Company concluding it had significant influence over the operations of Oragenics. The fair value of the Company’s equity securities of Oragenics was $22,161 and $10,129 as of December 31, 2013 and 2012, respectively, and is included as equity securities in the respective consolidated balance sheets. The Company’s ownership interest in Oragenics was 24.6% and 16.0% at December 31, 2013 and 2012, respectively. Unrealized appreciation (depreciation) in the fair value of the Company’s equity securities held in Oragenics was $(90) and $3,540 for the years ended December 31, 2013 and 2012, respectively. Summarized financial data for Oragenics as of December 31, 2013 and for the years ended December 31, 2013 and 2012 are as follows:
			December 31,
			2013
	Current assets		$	16,805
	Non-current assets			27
	Total assets			16,832
	Current liabilities			993
	Net assets		$	15,839
			Year ended
			December 31,
			2013			2012
	Revenues, net		$	1,032		$	1,332
	Gross profit			689			454
	Loss from operations			(16,210	)		(12,432	)
	Net loss		$	(16,069	)		(13,090	)
Variable Interest Entities	'
	Variable Interest Entities
	The Company identifies entities that (1) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (2) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (“VIE” or “VIEs”). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are a VIE. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (1) the power to direct activities that most significantly impact the VIE’s economic performance and (2) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of December 31, 2012, the Company determined that its investment in AquaBounty was a VIE. The Company was not the primary beneficiary for this entity since it did not have the power to direct the activities that most significantly impact the economic performance of the VIE. As of December 31, 2012, the total carrying value of the Company’s investment in the VIE was $5,726, which is the investment in AquaBounty. On March 15, 2013, the Company began consolidating AquaBounty since the Company’s ownership in AquaBounty exceeded 50% (Note 7). The Company’s maximum exposure to loss related to this VIE was limited to the carrying value of the investment.
	As of December 31, 2013, the Company determined that one of the its collaborators, Genopaver, LLC (“Genopaver”), was a VIE. The Company was not the primary beneficiary for this entity since it did not have the power to direct the activities that most significantly impact the economic performance of the VIE.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:
			Years
	Building			13
	Furniture and fixtures			7
	Lab equipment			2–7
	Computer hardware			5–7
	Software			3–5
	Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to four years.
Goodwill	'
	Goodwill
	Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized (Notes 3 and 7). Goodwill is reviewed for impairment at least annually. The Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the two-step goodwill impairment test. If this is the case, the two-step goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the two-step goodwill impairment test is not required.
	If the two-step goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must perform step two of the impairment test. Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. Fair value of the reporting unit is determined using a discounted cash flow analysis. If the fair value of the reporting unit exceeds its carrying amount, step two does not need to be performed.
	The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.
Intangible Assets	'
	Intangible Assets
	Intangible assets subject to amortization consist of patents and related technologies acquired as a result of mergers and acquisitions (Note 3). These intangible assets are subject to amortization and were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development acquired in a step acquisition (Note 7) and was recorded at fair value at the date of the step acquisition.
	The Company applies the provisions of ASC Topic 350, Intangibles, Goodwill and Other, which requires the amortization of long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their remaining estimated useful lives, ranging from seven to fourteen years for the patents and related technologies.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
	Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
	The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in general and administrative expenses.
Net Loss per Share	'
	Net Loss per Share
	Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Segment Information	'
	Segment Information
	The Company has determined that it operates in one segment. The Company uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company’s revenues are derived in the United States of America. Substantially all of the Company’s assets are located in the United States of America.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). ASU 2013-02 requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, companies would instead cross reference to the related footnote for additional information. ASU 2013-02 is effective for interim and annual reporting periods beginning after December 15, 2012. The Company has implemented the provisions of ASU 2013-02 as of January 1, 2013. The adoption of this amendment did not have a material impact on the Company’s consolidated financial statements.
	In July 2012, the FASB issued guidance intended to simplify indefinite-lived intangible impairment testing, by allowing an entity to first assess qualitative factors to determine whether it is “more likely than not” that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim tests performed for fiscal years beginning after September 15, 2012. The adoption of this guidance did not impact the Company’s consolidated financial statements.
	In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities (“ASU 2011-11”). ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (“IFRS”). The new standards are effective for annual periods beginning January 1, 2013 and interim periods within those annual periods. Retrospective application is required. The Company has implemented the provisions of ASU 2011-11 as of January 1, 2013. The adoption of this amendment did not have a material impact on the Company’s consolidated financial statements.
Reclassifications	'
	Reclassifications
	Certain insignificant reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Estimated Useful Lives	'
	The estimated useful lives of these assets are as follows:
		Years
	Building		13
	Furniture and fixtures		7
	Lab equipment		2–7
	Computer hardware		5–7
	Software		3–5
Oragenics, Inc	'
Summarized Unaudited Financial Information	'
	Summarized financial data for Oragenics as of December 31, 2013 and for the years ended December 31, 2013 and 2012 are as follows:
		December 31,
		2013
	Current assets	$	16,805
	Non-current assets		27
	Total assets		16,832
	Current liabilities		993
	Net assets	$	15,839
		Year ended
		December 31,
		2013			2012
	Revenues, net	$	1,032		$	1,332
	Gross profit		689			454
	Loss from operations		(16,210	)		(12,432	)
	Net loss	$	(16,069	)		(13,090	)
AquaBounty	'
Summarized Unaudited Financial Information	'
	Summarized unaudited financial information for AquaBounty as of December 31, 2012 and for the period from November 16, 2012 to December 31, 2012 is as follows:
		2012
	Current assets	$	514
	Non-current assets		1,962
	Total assets		2,476
	Current liabilities		706
	Non-current liabilities		2,741
	Total liabilities		3,447
	Net liabilities	$	(971	)
		2012
	Revenues	$	—
	Operating expenses		578
	Loss from operations		(578	)
	Other expense		(1	)
	Net loss	$	(579	)

Mergers_and_Acquisitions_Table

Mergers and Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Pro forma Financial Information	'
	The following unaudited condensed pro forma financial information for the year ended December 31, 2011 is presented as if the acquisitions had been consummated on January 1, 2011:
	(Unaudited)	2011
		Pro forma
	Revenues	$	9,146
	Net loss		(89,116	)
	Accretion of dividends on redeemable convertible preferred stock, not declared		(13,868	)
	Net loss attributable to common shareholders	$	(102,984	)
	Net loss attributable to common shareholders per share, basic and diluted	$	(19.01	)
Agarigen, Inc.	'
Acquisition Date Fair Value Consideration Transferred	'
	The acquisition date fair value of each class of consideration transferred was as follows:
	Cash	$	1,178
	Common shares		1,014
	Stock options and warrants		1,581
		$	3,773
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date	'
	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	334
	Trade receivables		53
	Other receivables		436
	Prepaid expenses and other		11
	Property and equipment		30
	Intangible assets		3,122
	Other assets		3
	Total assets acquired		3,989
	Accounts payable		60
	Accrued compensation and benefits		65
	Other accrued liabilities		91
	Total liabilities assumed		216
	Net assets acquired	$	3,773
GT Life Sciences, Inc.	'
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date	'
	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	21
	Other receivables		161
	Related party receivable		33
	Prepaid expenses and other		1
	Property and equipment		32
	Intangible assets		14,094
	Total assets acquired		14,342
	Accounts payable		55
	Accrued compensation and benefits		29
	Other accrued liabilities		8
	Total liabilities assumed		92
	Net assets acquired	$	14,250
Immunologix, Inc.	'
Acquisition Date Fair Value Consideration Transferred	'
	The acquisition date fair value of each class of consideration transferred was as follows:
	Cash	$	12,758
	Common shares		1,092
		$	13,850
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date	'
	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is as follows:
	Cash	$	19
	Other receivables		1
	Prepaid expenses and other		6
	Property and equipment		141
	Intangible assets		13,921
	Total assets acquired		14,088
	Accounts payable		87
	Accrued compensation and benefits		76
	Capital lease obligations		75
	Total liabilities assumed		238
	Net assets acquired	$	13,850
AquaBounty	'
Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date	'
	The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown in the table below along with subsequent adjustments during the measurement period to the fair value of assets acquired and liabilities assumed. The adjustments were due to the completed valuation of intangible assets and long-term debt.
		Initial estimated fair			Adjustments			Adjusted fair value
		value
	Cash	$	5,419		$			$	5,419
	Short-term investments		14			—			14
	Trade receivables		4			—			4
	Other receivables		9			—			9
	Prepaid expenses and other		200			—			200
	Property, plant and equipment		1,241			—			1,241
	Intangible assets		14,900			—			14,900
	Other assets		22			—			22
	Total assets acquired		21,809			—			21,809
	Accounts payable		156			—			156
	Accrued compensation		94			—			94
	Other accrued liabilities		395			—			395
	Long-term debt		2,199			(845	)		1,354
	Total liabilities assumed		2,844			(845	)		1,999
	Net assets acquired		18,965			845			19,810
	Goodwill		13,846			(845	)		13,001
	Total consideration	$	32,811		$	—		$	32,811
Condensed Pro forma Financial Information	'
	The following unaudited condensed pro forma financial information for the years ended December 31, 2013 and 2012, is presented as if the acquisition had been consummated on January 1, 2012:
		Year ended December 31,
		2013			2012
		Pro forma
	Revenues	$	23,760		$	13,774
	Net loss		(48,760	)		(78,651	)
	Net loss attributable to noncontrolling interest		2,310			2,062
	Net loss attributable to Intrexon		(46,450	)		(76,589	)
	Accretion of dividends on redeemable convertible preferred stock		(18,391	)		(21,994	)
	Net loss attributable to Intrexon common shareholders	$	(64,841	)	$	(98,583	)
	Net loss attributable to Intrexon common shareholders per share, basic and diluted	$	(1.58	)	$	(17.81	)
Summary of Fair Value of the Consideration Transferred	'
	The fair value of the consideration transferred included:
	Consideration paid	$	4,907
	Fair value of noncontrolling interest		15,153
	Fair value of the Company’s investment in affiliate held before the business combination		12,751
	Fair value of the consideration transferred	$	32,811

Collaboration_Revenue_Tables

Collaboration Revenue (Tables)	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Summarized Collaboration Revenues	'
	The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration for the years ended December 31, 2013, 2012 and 2011.
		Year ended December 31, 2013
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	2,577	$	7,818	$	10,395
	Synthetic Biologics, Inc.		2,187		1,048		3,235
	Oragenics, Inc.		673		1,517		2,190
	Fibrocell Science, Inc.		970		3,736		4,706
	Genopaver, LLC		204		935		1,139
	S & I Ophthalmic, LLC		—		417		417
	Other		333		1,110		1,443
	Total	$	6,944	$	16,581	$	23,525
		Year ended December 31, 2012
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	5,068	$	6,333	$	11,401
	Synthetic Biologics, Inc.		293		327		620
	Oragenics, Inc.		320		516		836
	Fibrocell Science, Inc.		158		61		219
	Other		12		618		630
	Total	$	5,851	$	7,855	$	13,706
		Year ended December 31, 2011
		Collaboration		Collaboration		Total
		revenue recognized		revenue recognized
		from upfront and		from research and
		milestone payments		development services
	ZIOPHARM Oncology, Inc.	$	2,372	$	2,724	$	5,096
	Synthetic Biologics, Inc.		22		—		22
	Total	$	2,394	$	2,724	$	5,118
Summary of Deferred Revenue	'
	Deferred revenue consists of the following:
		December 31,
		2013		2012
	Upfront and milestone payments	$	72,207	$	51,359
	Prepaid research and development services		1,319		7,229
	Other		45		48
	Total	$	73,571	$	58,636
	Current portion of deferred revenue		7,793		9,963
	Long-term portion of deferred revenue		65,778		48,673
	Total	$	73,571	$	58,636

Shortterm_and_Longterm_Investm1

Short-term and Long-term Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments	'
	The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2013:
		Amortized		Gross		Gross			Aggregate
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	U.S. government debt securities	$	178,277	$	35	$	(13	)	$	178,299
	Commercial paper		7,997		—		—			7,997
	Certificates of deposit		2,266		—		(1	)		2,265
	Total	$	188,540	$	35	$	(14	)	$	188,561
Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities	'
	The estimated fair value of available-for-sale investments classified by their contractual maturities as of December 31, 2013 was:
	Due within one year	$	127,980
	After one year through two years		60,581
	Total	$	188,561

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	'
	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2013:
		Quoted		Significant		Significant		December 31,
		prices		other		unobservable		2013
		in active		observable		inputs
		markets		inputs		(level 3)
		(level 1)		(level 2)
	Assets
	U.S. government debt securities (Note 5)	$	—	$	178,299	$	—	$	178,299
	Commercial paper (Note 5)		—		7,997		—		7,997
	Certificates of deposit (Note 5)		—		2,265		—		2,265
	Equity securities (Note 4)		110,297		31,228		—		141,525
		$	110,297	$	219,789	$	—	$	330,086
	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2012:
		Quoted		Significant		Significant		December 31,
		prices		other		unobservable		2012
		in active		observable		inputs
		markets		inputs		(level 3)
		(level 1)		(level 2)
	Assets
	Certificates of deposit (Note 5)	$	—	$	260	$	—	$	260
	Equity securities (Note 4)		72,988		10,128		—		83,116
		$	72,988	$	10,388	$	—	$	83,376

Property_Plant_and_Equipment_n1

Property, Plant and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
	Property, plant and equipment consist of the following:
		December 31,
		2013			2012
	Land	$	55		$	—
	Building		945			—
	Furniture and fixtures		876			857
	Lab equipment		22,275			22,195
	Leasehold improvements		5,147			4,972
	Computer hardware		3,286			3,136
	Construction in progress		314			14
	Software		1,008			888
			33,906			32,062
	Less: Accumulated depreciation and amortization		(17,277	)		(13,375	)
	Property, plant and equipment, net	$	16,629		$	18,687

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill for the year ended December 31, 2013 are as follows:
	Balance as of December 31, 2012	$	—
	Acquisitions		13,823
	Balance as of December 31, 2013	$	13,823
Schedule of Intangible Assets	'
	Intangible assets consist of the following at December 31, 2013:
		Gross Carrying		Accumulated			Net
		Amount		Amortization
	Patents and related technologies	$	34,772	$	(7,716	)	$	27,056
	In-process research and development		14,900		—			14,900
	Total	$	49,672	$	(7,716	)	$	41,956
	Intangible assets consist of the following at December 31, 2012:
		Gross Carrying		Accumulated			Net
		Amount		Amortization
	Patents and related technologies	$	34,342	$	(4,851	)	$	29,491
	Favorable rent asset		646		(631	)		15
	Total	$	34,988	$	(5,482	)	$	29,506

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation	'
	Income tax benefit for the years ended December 31, 2013, 2012 and 2011 differed from amounts computed by applying the applicable U.S. federal corporate income tax rate of 34% to loss before income taxes as a result of the following:
		2013			2012			2011
	Computed statutory income tax benefit	$	(13,909	)	$	(27,837	)	$	(28,995	)
	(Increase) reduction in income tax benefit resulting from State income tax benefit, net of federal income taxes		(1,834	)		(3,711	)		(3,893	)
	Nondeductible stock based compensation		575			333			203
	Contribution of services by shareholder		527			527			71
	Gain in previously held equity investment		(2,477	)		—			—
	Research and development tax credits		(1,203	)		—			(2,515	)
	Other, net		1,317			(238	)		477
			(17,004	)		(30,926	)		(34,652	)
	Change in valuation allowance for deferred tax assets		17,004			30,926			34,652
	Total income tax provision	$	—		$	—		$	—
Schedule of Deferred Tax Assets and Liabilities	'
	The tax effects of temporary differences that comprise the deferred tax assets and liabilities at December 31 are as follows:
		2013			2012
	Deferred tax assets
	Equity securities	$	415		$	4,346
	Accrued liabilities		1,445			1,910
	Stock-based compensation		1,677			363
	Deferred revenue		28,456			22,684
	Research and development tax credits		10,062			5,848
	Net operating loss carryforwards		97,395			80,159
	Total deferred tax assets		139,450			115,310
	Less: Valuation allowance		131,985			113,051
	Net deferred tax assets		7,465			2,259
	Deferred tax liabilities
	Property and equipment		140			478
	Intangible assets		7,325			1,781
	Total deferred tax liabilities		7,465			2,259
	Net deferred tax assets (liabilities)	$	—		$	—
Summary of Valuation Allowance	'
	Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2013, 2012 and 2011 was as follows:
		2013			2012			2011
	Valuation allowance at beginning of year	$	113,051		$	82,125		$	52,036
	(Decrease) increase in valuation allowance as a result of
	Mergers and acquisitions, net		1,930			—			(4,563	)
	Current year operations		17,004			30,926			34,652
	Valuation allowance at end of year	$	131,985		$	113,051		$	82,125

Redeemable_Convertible_Preferr1

Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Redeemable Convertible Preferred Stock	'
	The tables below represent a rollforward of the Redeemable Convertible Preferred Stock:
		Series A						Series B						Series B-1
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		705,400		$	802			694,000		$	639			1,212,360		$	1,300
	Accretion of dividends		—			556			—			30			—			60
	Balances at December 31, 2012		705,400			1,358			694,000			669			1,212,360			1,360
	Accretion of dividends		—			52			—			19			—			37
	Conversion to common stock		(705,400	)		(1,410	)		(694,000	)		(688	)		(1,212,360	)		(1,397	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series C						Series C-1						Series C-2
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		4,546,360		$	6,729			15,934,528		$	32,264			18,617,020		$	41,987
	Accretion of dividends		—			405			—			1,937			—			2,525
	Balances at December 31, 2012		4,546,360			7,134			15,934,528			34,201			18,617,020			44,512
	Accretion of dividends		—			266			—			1,272			—			1,660
	Conversion to common stock		(4,546,360	)		(7,400	)		(15,934,528	)		(35,473	)		(18,617,020	)		(46,172	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series C-3						Series D						Series E
		redeemable						redeemable						redeemable
		convertible						convertible						convertible
		preferred stock						preferred stock						preferred stock
		Shares			Amount			Shares			Amount			Shares			Amount
	Balances at December 31, 2011		13,297,872		$	28,082			19,803,685		$	71,924			22,285,716		$	117,954
	Issuance of shares		—			—			—			—			15,809,523			83,000
	Accretion of dividends		—			1,688			—			4,328			—			10,465
	Stock issuance costs		—			—			—			—			—			(16	)
	Balances at December 31, 2012		13,297,872			29,770			19,803,685			76,252			38,095,239			211,403
	Accretion of dividends		—			1,103			—			2,827			—			7,931
	Conversion to common stock		(13,297,872	)		(30,873	)		(19,803,685	)		(79,078	)		(38,095,239	)		(219,332	)
	Settlement of fractional shares upon conversion to common stock		—			—			—			(1	)		—			(2	)
	Balances at December 31, 2013		—		$	—			—		$	—			—		$	—
		Series F
		redeemable
		convertible
		preferred stock
		Shares			Amount
	Balances at December 31, 2012		—		$	—
	Issuance of shares		19,047,619			150,000
	Accretion of dividends		—			3,224
	Stock issuance costs		—			(3,148	)
	Conversion to common stock		(19,047,619	)		(150,075	)
	Settlement of fractional shares upon conversion to common stock		—			(1	)
	Balances at December 31, 2013		—		$	—

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Assumptions Used in Pricing Model	'
	The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2013, 2012 and 2011 are set forth below:
			2013		2012	2011
	Valuation assumptions
	Expected dividend yield		0%		0%	0%
	Expected volatility		73%—75%		71%—76%	68%—72%
	Expected term (years)		6.25		6	5.37— 6.23
	Risk-free interest rate		0.96%—1.86%		0.80%—1.10%	1.34%—2.51%
Schedule of Stock Option Activity	'
	Stock option activity was as follows:
			Number of			Weighted			Weighted
			shares			average			average
						exercise			remaining
						price			contractual
									term
	Balances at December 31, 2010			1,448,145		$	2.71			6.99
	Granted			2,429,684			6.48
	Exercised			(75,840	)		(2.43	)
	Forfeited			(145,214	)		(3.34	)
	Expired			(42,245	)		(2.94	)
	Balances at December 31, 2011			3,614,530			5.22			6.67
	Granted			548,571			7.12
	Exercised			(194,570	)		(2.43	)
	Forfeited			(1,210,857	)		(6.30	)
	Expired			(444,148	)		(2.29	)
	Balances at December 31, 2012			2,313,526			5.9			7.87
	Granted			989,709			13.06
	Exercised			(88,764	)		(6.04	)
	Forfeited			(335,746	)		(6.94	)
	Expired			(38,077	)		(5.17	)
	Balances at December 31, 2013			2,840,648			8.27			7.75
	Exercisable at December 31, 2013			1,227,563			5.37			6.44
	Vested and Expected to Vest at December 31, 2013(1)			2,469,860			7.8			7.57
	-1	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
Summary of Additional Information About Stock Options	'
	The following table summarizes additional information about stock options outstanding as of December 31, 2013:
	Options outstanding										Options exercisable
	Exercise price		Number of			Weighted			Aggregate		Number of		Weighted		Aggregate
			options			average			intrinsic		options		average		intrinsic
						remaining			value				remaining		value
						life (years)							life
													(years)
	$0.39			57,263			5.72		$	1,341		57,263		5.72	$	1,341
	$1.34			106,776			2.1			2,398		106,776		2.1		2,398
	$1.92			12,855			3.22			281		12,855		3.22		281
	$2.74			175,040			3.66			3,686		175,040		3.66		3,686
	$3.29			156,055			6.14			3,201		143,411		6.1		2,941
	$5.91			150,062			7.15			2,685		75,771		7.07		1,356
	$7.12			1,194,887			7.8			19,931		546,805		7.77		9,121
	$9.67			701,710			9.41			9,915		107,142		9.41		1,514
	$19.83			225,500			9.96			895		—		—		—
	$26.76			42,500			9.69			—		—		—		—
	$28.69			18,000			9.62			—		2,500		9.62		—
				2,840,648			7.75		$	44,333		1,227,563		6.44	$	22,638
	The following table summarizes additional information about stock options outstanding as of December 31, 2012:
	Options outstanding										Options exercisable
	Exercise price		Number of			Weighted			Aggregate		Number of		Weighted		Aggregate
			options			average			intrinsic		options		average		intrinsic
						remaining			value				remaining		value
						life (years)							life
													(years)
	$0.39			57,263			8.07		$	385		57,263		8.07	$	385
	$1.34			106,776			3.1			617		106,776		3.1		617
	$1.92			23,145			4.25			120		23,145		4.25		120
	$2.74			186,286			4.62			815		186,286		4.62		815
	$3.29			183,442			6.77			703		126,014		6.72		483
	$5.91			169,857			7.64			205		42,571		7.59		51
	$7.12			1,586,757			8.77			—		266,578		8.53		—
				2,313,526			7.87		$	2,845		808,633		6.43	$	2,471

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments Under Noncancelable Operating Leases	'
	At December 31, 2013, future minimum lease payments under noncancelable operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:
	2014	$	3,661
	2015		3,408
	2016		2,687
	2017		1,419
	2018		72
			11,247

Related_Party_Transactions_Tab

Related Party Transactions (Tables) (Cyntellect, Inc.)	12 Months Ended
	Dec. 31, 2013
Cyntellect, Inc.	'
Summary of Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date	'
	The carrying amounts of the assets acquired and liabilities assumed is as follows:
	Cash	$	88
	Other current assets		23
	Property and equipment, net		1,724
	Other assets		262
	Total assets acquired		2,097
	Accounts payable		41
	Other accrued liabilities		107
	Long-term debt		116
	Total liabilities assumed		264
	Net assets acquired	$	1,833

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Historical Computation of Basic and Diluted Net Loss per Share	'
	The following table presents the historical computation of basic and diluted net loss per share:
		Year ended
		December 31,
		2013			2012			2011
	Historical net loss per share:
	Numerator:
	Net loss	$	(38,980	)	$	(81,874	)	$	(85,280	)
	Add: Accretion of dividends on redeemable convertible preferred stock		(18,391	)		(21,994	)		(13,868	)
	Net loss attributable to common shareholders		(57,371	)		(103,868	)		(99,148	)
	Denominator:
	Weighted average shares outstanding, basic and diluted		40,951,952			5,533,690			5,240,647
	Net loss attributable to common shareholders per share, basic and diluted	$	(1.40	)	$	(18.77	)	$	(18.92	)
Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share	'
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of December 31, 2013, 2012, and 2011, as they would have been anti-dilutive:
		December 31,
		2013			2012			2011
	Common shares issuable upon conversion of all Series Preferred		—			64,517,977			55,483,966
	Options		2,840,648			2,313,526			3,614,530
	Warrants		414,404			511,098			511,098
	Total		3,255,052			67,342,601			59,609,594

Quarterly_Financial_Informatio1

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information (Unaudited)	'
	The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information.
		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Total revenues	$	3,885		$	6,690		$	6,042		$	7,143
	Operating loss	$	(14,006	)	$	(14,254	)	$	(12,037	)	$	(17,726	)
	Net income (loss)	$	(36,362	)	$	(6,519	)	$	14,991		$	(13,018	)
	Net income (loss) attributable to Intrexon	$	(36,311	)	$	(5,905	)	$	15,440		$	(12,204	)
	Net income (loss) attributable to common shareholders per share, basic	$	(7.54	)	$	(2.44	)	$	0.15		$	(0.13	)
	Net income (loss) attributable to common shareholders per share, diluted	$	(7.54	)	$	(2.44	)	$	0.15		$	(0.13	)
		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Total revenues	$	1,564		$	2,716		$	2,925		$	6,569
	Operating loss	$	(25,121	)	$	(21,248	)	$	(16,485	)	$	(12,303	)
	Net loss	$	(13,912	)	$	(16,535	)	$	(20,490	)	$	(30,937	)
	Net loss attributable to common shareholders per share, basic and diluted	$	(3.55	)	$	(3.99	)	$	(4.66	)	$	(6.52	)

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended					1 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 13, 2013	Jul. 26, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Oct. 31, 2013	Aug. 13, 2013	Aug. 13, 2013
					AquaBounty	BioPop	BioPop	IPO	Exercise of Overallotment Option by Underwriters
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'	'	'	'	'	'	'	'	'
Percentage of outstanding common stock acquired	'	'	'	'	54.00%	51.00%	51.00%	'	'
Reverse stock split ratio	'	'1-for-1.75	'	'	'	'	'	'	'
Reverse stock split ratio	'	0.57143	'	'	'	'	'	'	'
Shares of common stock	'	'	'	'	'	'	'	11,499,998	1,499,999
Price per share of common stock	'	'	'	'	'	'	'	$16	'
Aggregate proceeds from the IPO	'	'	$168,801	'	'	'	'	$168,300	'
Underwriting discounts and commissions	'	'	'	'	'	'	'	12,900	'
Offering Expense paid	'	'	'	'	'	'	'	2,800	'
Capitalized expenses	'	'	'	'	'	'	'	$2,300	'
Shares of common stock	79,705,130	'	'	'	'	'	'	'	'
Number of authorized shares of common stock	200,000,000	'	200,000,000	160,000,000	'	'	'	'	'
Number of authorized shares of preferred stock	25,000,000	'	'	'	'	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment	Entity
	Entity
Organization And Significant Accounting Policies [Line Items]	'	'	'
Research and development commitments with third parties	$2,445	$3,164	'
Research and development commitments with third parties not incurred	957	1,431	'
Maturity period of liquid investment	'3 months	'	'
Cash equivalent investments in highly liquid money market accounts	43,733	9,384	'
Investments gross unrealized losses	14	'	'
Number of collaborators over which the Company has significant influence	2	1	'
Fair value of financial assets measured at fair value on a recurring basis	330,086	83,376	'
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities	10,443	-6,290	-2,675
Carrying value of investment in VIEs	'	5,726	'
Number of collaborators identified as VIEs	1	'	'
Percentage of recognized income tax positions	50.00%	'	'
Number of segment	1	'	'
Equity Securities	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Fair value of financial assets measured at fair value on a recurring basis	141,525	83,116	'
Ziopharm	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Company's ownership percentage	16.40%	16.30%	'
Ziopharm | Equity Securities	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Fair value of financial assets measured at fair value on a recurring basis	71,134	56,298	'
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities	4,836	-7,194	-4,924
Oragenics, Inc	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Company's ownership percentage	24.60%	16.00%	'
Oragenics, Inc | Equity Securities	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Fair value of financial assets measured at fair value on a recurring basis	22,161	10,129	'
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities	($90)	$3,540	'
Minimum | Patents and Related Technologies	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Period of estimated useful lives	'7 years	'	'
Minimum | Leasehold Improvements	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Property plant and equipment, useful life	'1 year	'	'
Maximum | Patents and Related Technologies	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Period of estimated useful lives	'14 years	'	'
Maximum | Leasehold Improvements	'	'	'
Organization And Significant Accounting Policies [Line Items]	'	'	'
Property plant and equipment, useful life	'4 years	'	'

Summarized_Financial_Data_Deta

Summarized Financial Data (Detail) (Oragenics, Inc, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Oragenics, Inc	'	'
Schedule of Equity Method Investments [Line Items]	'	'
Current assets	$16,805	'
Non-current assets	27	'
Total assets	16,832	'
Current liabilities	993	'
Net assets	15,839	'
Revenues, net	1,032	1,332
Gross profit	689	454
Loss from operations	-16,210	-12,432
Net Loss	($16,069)	($13,090)

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Building	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'13 years
Furniture and Fixtures	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'7 years
Minimum | Lab Equipment	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'2 years
Minimum | Computer hardware	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'5 years
Minimum | Software	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'3 years
Maximum | Lab Equipment	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'7 years
Maximum | Computer hardware	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'7 years
Maximum | Software	'
Property, Plant and Equipment [Line Items]	'
Property plant and equipment, useful life	'5 years

Business_Acquisitions_Agarigen

Business Acquisitions - Agarigen, Inc. - Additional Information (Detail) (Agarigen, Inc., USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 26, 2011	Dec. 31, 2011
Business Acquisition [Line Items]	'	'
Percentage of outstanding common stock acquired	100.00%	'
Fair Value of Consideration Transferred	$3,773	'
Business acquisition, consideration paid, shares issued	386,142	'
Business acquisition, options to purchase common stock issued	165,255	'
Business acquisition, warrants to purchase common stock issued	511,098	'
Business acquisition, warrants to purchase common stock, price per share	0.79	'
Business combination, acquisition related costs	'	110
Warrant Expiration Year	'2017-12	'
Minimum	'	'
Business Acquisition [Line Items]	'	'
Business acquisition, Common Stock Strike Price	0.38	'
Maximum	'	'
Business Acquisition [Line Items]	'	'
Business acquisition, Common Stock Strike Price	1.98	'
Patents and Related Technologies	'	'
Business Acquisition [Line Items]	'	'
Acquired Intangible Assets, useful life	'9 years	'
Cash	'	'
Business Acquisition [Line Items]	'	'
Fair Value of Consideration Transferred	$1,178	'

Fair_Value_of_Consideration_Tr

Fair Value of Consideration Transferred - Agarigen, Inc (Detail) (Agarigen, Inc., USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jan. 26, 2011
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$3,773
Cash	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	1,178
Common Stock	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	1,014
Stock Options and Warrants	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$1,581

Fair_Value_of_Assets_Acquired_

Fair Value of Assets Acquired and Liabilities Assumed - Agarigen, Inc. (Detail) (Agarigen, Inc., USD $)	Jan. 26, 2011
In Thousands, unless otherwise specified
Agarigen, Inc.	'
Business Acquisition [Line Items]	'
Cash	$334
Trade receivables	53
Other receivables	436
Prepaid expenses and other	11
Property and equipment	30
Intangible assets	3,122
Other assets	3
Total assets acquired	3,989
Accounts payable	60
Accrued compensation and benefits	65
Other accrued liabilities	91
Total liabilities assumed	216
Net assets acquired	$3,773

Business_Acquisitions_GT_Life_

Business Acquisitions - GT Life Sciences, Inc. - Additional Information (Detail) (GT Life Sciences, Inc., USD $)	12 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011	Oct. 05, 2011	Oct. 05, 2011	Oct. 05, 2011
			Patents and Related Technologies	Cash
Business Acquisition [Line Items]	'	'	'	'
Percentage of outstanding common stock acquired	'	100.00%	'	'
Fair Value of Consideration Transferred	'	'	'	$14,250
Acquired Intangible Assets, useful life	'	'	'13 years	'
Business combination, acquisition related cost	$276	'	'	'

Fair_Value_of_Assets_Acquired_1

Fair Value of Assets Acquired and Liabilities Assumed - GT Life Sciences, Inc. (Detail) (GT Life Sciences, Inc., USD $)	Oct. 05, 2011
In Thousands, unless otherwise specified
GT Life Sciences, Inc.	'
Business Acquisition [Line Items]	'
Cash	$21
Other receivables	161
Related party receivable	33
Prepaid expenses and other	1
Property and equipment	32
Intangible assets	14,094
Total assets acquired	14,342
Accounts payable	55
Accrued compensation and benefits	29
Other accrued liabilities	8
Total liabilities assumed	92
Net assets acquired	$14,250

Business_Acquisitions_Immunolo

Business Acquisitions - Immunologix, Inc. - Additional Information (Detail) (Immunologix, Inc., USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 21, 2011	Dec. 31, 2011
Business Acquisition [Line Items]	'	'
Percentage of outstanding common stock acquired	100.00%	'
Fair Value of Consideration Transferred	$13,850	'
Business acquisition, consideration paid, shares issued	153,365	'
Business acquisition, percentage of consideration required	50.00%	'
Potential Contingent Consideration Arrangement	0	'
Potential Contingent Consideration Arrangement	2,000	'
Fair value of the contingent consideration arrangement	0	'
Business combination, acquisition related cost	'	293
Patents and Related Technologies	'	'
Business Acquisition [Line Items]	'	'
Acquired Intangible Assets, useful life	'13 years	'
Cash	'	'
Business Acquisition [Line Items]	'	'
Fair Value of Consideration Transferred	$12,758	'

Acquisition_Date_Fair_Value_of

Acquisition Date Fair Value of Each Class of Consideration Transferred - Immunologix, Inc. (Detail) (Immunologix, Inc., USD $)	1 Months Ended
In Thousands, unless otherwise specified	Oct. 21, 2011
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$13,850
Cash	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	12,758
Common Stock	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$1,092

Fair_Value_of_Assets_Acquired_2

Fair Value of Assets Acquired and Liabilities Assumed - Immunologix, Inc. (Detail) (Immunologix, Inc., USD $)	Oct. 21, 2011
In Thousands, unless otherwise specified
Immunologix, Inc.	'
Business Acquisition [Line Items]	'
Cash	$19
Other receivables	1
Prepaid expenses and other	6
Property and equipment	141
Intangible assets	13,921
Total assets acquired	14,088
Accounts payable	87
Accrued compensation and benefits	76
Capital lease obligations	75
Total liabilities assumed	238
Net assets acquired	$13,850

Business_Acquisitions_Other_20

Business Acquisitions - Other 2011 Acquisitions - Additional Information (Detail) (Other 2011 Acquisition, USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 30, 2011
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$1,400
Patents and Related Technologies	'
Business Acquisition [Line Items]	'
Acquired Intangible Assets, useful life	'13 years
Cash	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	850
Common Stock	'
Business Acquisition [Line Items]	'
Fair Value of Consideration Transferred	$550
Business acquisition, consideration paid, shares issued	92,984

Disclosure_Pro_Forma_Financial

Disclosure - Pro Forma Financial Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Accretion of dividends on redeemable convertible preferred stock	'	'	'	'	'	'	'	'	($18,391)	($21,994)	($13,868)
Net loss attributable to common shareholders	-12,204	15,440	-5,905	-36,311	'	'	'	'	-57,371	-103,868	-99,148
Net loss attributable to common shareholders per share, basic and diluted	'	'	'	'	($6.52)	($4.66)	($3.99)	($3.55)	($1.40)	($18.77)	($18.92)
Pro Forma	'	'	'	'	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	'	'	9,146
Net loss	'	'	'	'	'	'	'	'	'	'	-89,116
Accretion of dividends on redeemable convertible preferred stock	'	'	'	'	'	'	'	'	'	'	-13,868
Net loss attributable to common shareholders	'	'	'	'	'	'	'	'	'	'	($102,984)
Net loss attributable to common shareholders per share, basic and diluted	'	'	'	'	'	'	'	'	'	'	($19.01)

Business_Acquisitions_BioPop_A

Business Acquisitions - BioPop Acquisition - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013
In Thousands, unless otherwise specified			BioPop	BioPop	BioPop	BioPop
					Patents and Related Technologies	Cash
Business Acquisition [Line Items]	'	'	'	'	'	'
Fair Value of Consideration Transferred	'	'	'	'	'	$1,300
Percentage of outstanding shares acquired	'	'	51.00%	51.00%	'	'
Goodwill	13,823	'	'	822	'	'
Intangible Asset	'	'	'	$430	'	'
Acquired Intangible Assets, useful life	'	'	'	'	'4 years	'

Summarized_Amount_of_Collabora

Summarized Amount of Collaboration Recorded in Consolidated Statement of Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	$23,525	$13,706	$5,118
ZIOPHARM Oncology, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	10,395	11,401	5,096
Synthetic Biologics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	3,235	620	22
Oragenics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	2,190	836	'
Fibrocell Science, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	4,706	219	'
Genopaver, LLC	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	1,139	'	'
S & I Ophthalmic, LLC	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	417	'	'
Other Collaborations	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	1,443	630	'
Upfront and Milestone Payments	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	6,944	5,851	2,394
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	2,577	5,068	2,372
Upfront and Milestone Payments | Synthetic Biologics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	2,187	293	22
Upfront and Milestone Payments | Oragenics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	673	320	'
Upfront and Milestone Payments | Fibrocell Science, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	970	158	'
Upfront and Milestone Payments | Genopaver, LLC	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	204	'	'
Upfront and Milestone Payments | Other Collaborations	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	333	12	'
Research And Development Services	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	16,581	7,855	2,724
Research And Development Services | ZIOPHARM Oncology, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	7,818	6,333	2,724
Research And Development Services | Synthetic Biologics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	1,048	327	'
Research And Development Services | Oragenics, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	1,517	516	'
Research And Development Services | Fibrocell Science, Inc.	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	3,736	61	'
Research And Development Services | Genopaver, LLC	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	935	'	'
Research And Development Services | S & I Ophthalmic, LLC	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	417	'	'
Research And Development Services | Other Collaborations	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaboration revenues	$1,110	$618	'

Collaboration_Revenue_Addition

Collaboration Revenue - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 06, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 21, 2012

Nov. 18, 2011

Aug. 06, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 17, 2012

Jun. 05, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Oct. 05, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 14, 2013

Oct. 24, 2012

Jan. 06, 2011

Nov. 18, 2011

Oct. 05, 2012

Jun. 05, 2012

Sep. 30, 2013

Dec. 31, 2013

Oct. 05, 2012

Mar. 31, 2013

Jan. 06, 2011

Jun. 28, 2013

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Research And Development Services

Research And Development Services

Research And Development Services

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

Synthetic Biologics, Inc

Synthetic Biologics Field Two Ecc

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics, Inc.

Oragenics Second Ecc

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Fibrocell Science, Inc.

Genopaver, LLC

Genopaver, LLC

Genopaver, LLC

Genopaver, LLC

Aqua Bounty Ecc

Milestone One

Upfront

Upfront

Upfront

Upfront

Upfront

Upfront

Upfront

Upfront

Upfront

Supplemental Upfront

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Research And Development Services

Research And Development Services

Research And Development Services

Research And Development Services

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Research And Development Services

Research And Development Services

Research And Development Services

Upfront and Milestone Payments

Upfront and Milestone Payments

Research And Development Services

Research And Development Services

Upfront and Milestone Payments

Upfront and Milestone Payments

Research And Development Services

Research And Development Services

Upfront and Milestone Payments

Research And Development Services

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

Synthetic Biologics, Inc

Synthetic Biologics Field Two Ecc

Oragenics, Inc.

Oragenics Second Ecc

Oragenics Second Ecc

Fibrocell Science, Inc.

Genopaver, LLC

Unit of Accounting 1

Fibrocell Science Ecc Unit Of Accounting One

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Upfront and Milestone Payments

Collaboration Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement consideration received, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,636,926

3,636,926

3,123,558

3,552,210

4,392,425

1,348,000

'

1,317,520

'

'

1,243,781

Collaborative arrangement consideration received, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$18,330

$17,457

$1,687

$7,815

$6,588

$3,503

'

$7,576

$3,000

'

'

Collaboration revenue

23,525

13,706

5,118

6,944

5,851

2,394

16,581

7,855

2,724

'

10,395

11,401

5,096

2,577

5,068

2,372

7,818

6,333

2,724

'

'

'

3,235

620

22

2,187

293

22

1,048

327

'

'

2,190

836

673

320

1,517

516

'

'

4,706

219

970

158

3,736

61

'

1,139

204

935

'

'

'

'

'

'

'

'

'

'

1,115

'

Deferred revenue

73,571

58,636

'

72,207

51,359

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,342

7,612

Percent of shares outstanding at the date of achievement of future milestone

'

'

'

'

'

'

'

'

'

7.50%

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty rate as a percentage of net profit

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Required notice period for voluntary termination of collaborative agreement

'

'

'

'

'

'

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

'90 days

'90 days

'

'

'

'

'

'

'

'

'

'90 days

'

'

'

'

'

'

'90 days

'90 days

'

'

'

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period when agreement cannot be voluntarily terminated

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'18 months

'18 months

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration to be received upon achievement of future milestone 1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration to be received upon achievement of future milestone 2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

Field expansion fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares outstanding at the date of achievement of future milestone 2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares outstanding at the date of achievement of future milestone 3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares outstanding at the date of achievement of future milestone 4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares outstanding at the date of achievement of future milestone 5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity date of promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'December 31, 2013

'

'

'

'

'

Collaborative arrangement consideration received, value of convertible promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,956

'

'

'

'

'

Consideration to be received upon achievement of future milestone 3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty rate as a percentage of net sales, tier 1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of promissory note into Common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

698,241

'

'

'

'

Number of reverse stock split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1-for-25 reverse stock split

'

'

'

Royalty rate as a percentage of net sales, tier 2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty rate of savings from improvement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Level of net sales at which royalty rate changes to tier 2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty rate as a percentage of gross profit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16.66%

'

'

'

'

'

'

'

'

'

'

'

Collaboration_Revenue_Summary_

Collaboration Revenue - Summary of Deferred Revenue (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]	'	'
Current portion of deferred revenue	$7,793	$9,963
Long-term portion of deferred revenue	65,778	48,673
Deferred revenue	73,571	58,636
Upfront and Milestone Payments	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	72,207	51,359
Prepaid Research And Development Services	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	1,319	7,229
Other	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	$45	$48

Shortterm_and_Longterm_Investm2

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term Investments (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	$188,540
Gross Unrealized Gains	35
Gross Unrealized Losses	-14
Aggregate Fair Value	188,561
U.S. government debt securities	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	178,277
Gross Unrealized Gains	35
Gross Unrealized Losses	-13
Aggregate Fair Value	178,299
Commercial Paper	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	7,997
Aggregate Fair Value	7,997
Certificates of Deposit	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	2,266
Gross Unrealized Losses	-1
Aggregate Fair Value	$2,265

Shortterm_and_Longterm_Investm3

Short-term and Long-term Investments - Summary of Estimated Fair Value of Available-for-Sale Investments Classified by Contractual Maturities (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Amortized Cost And Fair Value Debt Securities [Abstract]	'
Due within one year	$127,980
After one year through two years	60,581
Aggregate Fair Value	$188,561

Shortterm_and_Longterm_Investm4

Short-term and Long-term Investments - Additional Information (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Amortized Cost And Fair Value Debt Securities [Abstract]	'
Unrealized losses	$14
Fair value of investments with unrealized losses	$80,176

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Fair value of assets	$330,086	$83,376
US Government Debt Securities	'	'
Assets	'	'
Fair value of assets	178,299	'
Commercial Paper	'	'
Assets	'	'
Fair value of assets	7,997	'
Certificates of Deposit	'	'
Assets	'	'
Fair value of assets	2,265	260
Equity Securities	'	'
Assets	'	'
Fair value of assets	141,525	83,116
Quoted prices in active markets (level 1)	'	'
Assets	'	'
Fair value of assets	110,297	72,988
Quoted prices in active markets (level 1) | Equity Securities	'	'
Assets	'	'
Fair value of assets	110,297	72,988
Significant other observable inputs (level 2)	'	'
Assets	'	'
Fair value of assets	219,789	10,388
Significant other observable inputs (level 2) | US Government Debt Securities	'	'
Assets	'	'
Fair value of assets	178,299	'
Significant other observable inputs (level 2) | Commercial Paper	'	'
Assets	'	'
Fair value of assets	7,997	'
Significant other observable inputs (level 2) | Certificates of Deposit	'	'
Assets	'	'
Fair value of assets	2,265	260
Significant other observable inputs (level 2) | Equity Securities	'	'
Assets	'	'
Fair value of assets	$31,228	$10,128

Investment_in_AquaBounty_Addit

Investment in AquaBounty - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 15, 2013

Nov. 29, 2012

Nov. 16, 2012

Feb. 28, 2013

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

AquaBounty

AquaBounty

AquaBounty

AquaBounty

AquaBounty

AquaBounty

AquaBounty

AquaBounty

AquaBounty

Pro Forma

In- Process Research and Development

Business Combination, Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares acquired

'

'

'

'

'

48,631,444

'

'

'

'

'

'

Percentage of outstanding shares

'

'

'

'

'

47.56%

'

'

'

'

'

'

Definitive purchase agreement amount

'

'

'

'

'

$6,000

'

'

'

'

'

'

Carrying amount of the investment

6,284

5,726

'

'

'

'

'

'

'

5,726

'

'

Fair value of the investment

'

'

'

'

'

'

'

'

'

14,300

'

'

Amount of loan allowed in promissory note

'

'

'

'

500

'

'

'

'

'

'

'

Annual interest rate

'

'

'

'

3.00%

'

'

'

'

'

'

'

Amount drawn on promissory note

'

'

'

'

'

'

100

200

'

200

'

'

Promissory note repaid

500

34

300

500

'

'

'

'

'

'

'

'

Maturity date of promissory note

'

'

'

'

'May 28, 2013

'

'

'

'

'

'

'

Number of shares acquired

'

'

'

18,714,814

'

'

'

'

'

'

'

'

Amount from private subscription offering

'

'

'

4,907

'

'

'

'

'

'

'

'

Aggregate percentage of ownership

'

'

'

53.82%

'

'

'

'

'

'

'

'

Gain recognized

$7,415

'

'

$7,415

'

'

'

'

$7,415

'

$7,415

'

Percentage of equity interest previously held

'

'

'

47.56%

'

'

'

'

'

'

'

'

Expected useful life of intangible asset

'

'

'

'

'

'

'

'

'

'

'

'15 years

Summarized_Unaudited_Financial

Summarized Unaudited Financial Information for AquaBounty (Detail) (AquaBounty, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
AquaBounty	'
Schedule of Equity Method Investments [Line Items]	'
Current assets	$514
Non-current assets	1,962
Total Assets	2,476
Current liabilities	706
Non-current liabilities	2,741
Total liabilities	3,447
Net liabilities	-971
Revenues	'
Operating expenses	578
Loss from operations	-578
Other expense	-1
Net loss	($579)

Investment_in_AquaBounty_Summa

Investment in AquaBounty - Summary of Fair Value of the Consideration Transferred (Detail) (AquaBounty, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Mar. 15, 2013
AquaBounty	'
Business Acquisition [Line Items]	'
Consideration paid	$4,907
Fair value of noncontrolling interest	15,153
Fair value of the Company's investment in affiliate held before the business combination	12,751
Fair value of the consideration transferred	$32,811

Investment_in_AquaBounty_Summa1

Investment in AquaBounty - Summary of Estimated Fair Value of Assets Acquired and Liabilities Assumed at the Acquisition Date (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'
Goodwill	$13,823	'
AquaBounty | Scenario, Plan	'	'
Business Acquisition [Line Items]	'	'
Cash	5,419	'
Short-term investments	14	'
Trade receivables	4	'
Other receivables	9	'
Prepaid expenses and other	200	'
Property, plant and equipment	1,241	'
Intangible assets	14,900	'
Other assets	22	'
Total assets acquired	21,809	'
Accounts payable	156	'
Accrued compensation	94	'
Other accrued liabilities	395	'
Long-term debt	2,199	'
Total liabilities assumed	2,844	'
Net assets acquired	18,965	'
Goodwill	13,846	'
Total consideration	32,811	'
AquaBounty | Scenario, Adjustment	'	'
Business Acquisition [Line Items]	'	'
Long-term debt	-845	'
Total liabilities assumed	-845	'
Net assets acquired	845	'
Goodwill	-845	'
AquaBounty | Scenario, Actual	'	'
Business Acquisition [Line Items]	'	'
Cash	5,419	'
Short-term investments	14	'
Trade receivables	4	'
Other receivables	9	'
Prepaid expenses and other	200	'
Property, plant and equipment	1,241	'
Intangible assets	14,900	'
Other assets	22	'
Total assets acquired	21,809	'
Accounts payable	156	'
Accrued compensation	94	'
Other accrued liabilities	395	'
Long-term debt	1,354	'
Total liabilities assumed	1,999	'
Net assets acquired	19,810	'
Goodwill	13,001	'
Total consideration	$32,811	'

Investment_in_AquaBounty_Summa2

Investment in AquaBounty - Summary of Unaudited Condensed Pro Forma Financial Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition, Pro Forma Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net loss	($13,018)	$14,991	($6,519)	($36,362)	($30,937)	($20,490)	($16,535)	($13,912)	($40,908)	($81,874)	($85,280)
Net loss attributable to noncontrolling interest	'	'	'	'	'	'	'	'	1,928	'	'
Accretion of dividends on redeemable convertible preferred stock	'	'	'	'	'	'	'	'	-18,391	-21,994	-13,868
Net loss attributable to common shareholders	-12,204	15,440	-5,905	-36,311	'	'	'	'	-57,371	-103,868	-99,148
Net loss attributable to Intrexon common shareholders per share, basic and diluted	'	'	'	'	($6.52)	($4.66)	($3.99)	($3.55)	($1.40)	($18.77)	($18.92)
Pro Forma	'	'	'	'	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	'	'	9,146
Net loss attributable to Intrexon	'	'	'	'	'	'	'	'	'	'	-89,116
Net loss attributable to common shareholders	'	'	'	'	'	'	'	'	'	'	-102,984
Net loss attributable to Intrexon common shareholders per share, basic and diluted	'	'	'	'	'	'	'	'	'	'	($19.01)
Pro Forma | AquaBounty	'	'	'	'	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	23,760	13,774	'
Net loss	'	'	'	'	'	'	'	'	-48,760	-78,651	'
Net loss attributable to noncontrolling interest	'	'	'	'	'	'	'	'	2,310	2,062	'
Net loss attributable to Intrexon	'	'	'	'	'	'	'	'	-46,450	-76,589	'
Accretion of dividends on redeemable convertible preferred stock	'	'	'	'	'	'	'	'	-18,391	-21,994	'
Net loss attributable to common shareholders	'	'	'	'	'	'	'	'	($64,841)	($98,583)	'
Net loss attributable to Intrexon common shareholders per share, basic and diluted	'	'	'	'	'	'	'	'	($1.58)	($17.81)	'

Investment_in_S_I_Ophthalmic_A

Investment in S & I Ophthalmic - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			S & I Ophthalmic, LLC	S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]	'	'	'	'
Initial capital contribution	'	'	$5,000	'
Membership interest	'	'	50.00%	'
Total Assets	'	'	'	9,850
Total Liabilities	'	'	'	283
Net Loss	'	'	'	433
Investment	$6,284	$5,726	'	$4,784

Investment_in_OvaXon_Additiona

Investment in OvaXon - Additional Information (Detail) (OvaXon, Subsequent Event, USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014
OvaXon | Subsequent Event	'
Schedule Of Investments In Joint Venture [Line Items]	'
Initial capital contribution	$1,500
Membership interest	50.00%

Recovered_Sheet1

Property, Plant and Equipment, Net - Schedule of Property Plant and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]	'	'
Land	$55	'
Building	945	'
Furniture and fixtures	876	857
Lab equipment	22,275	22,195
Leasehold improvements	5,147	4,972
Computer hardware	3,286	3,136
Construction in progress	314	14
Software	1,008	888
Property, plant and equipment, gross	33,906	32,062
Less: Accumulated depreciation and amortization	-17,277	-13,375
Property, plant and equipment, net	$16,629	$18,687

Recovered_Sheet2

Property, Plant and Equipment, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment [Abstract]	'	'	'
Depreciation expense	$4,325	$4,957	$3,078

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Beginning Balance	'
Acquisitions	13,823
Ending Balance	$13,823

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Intangible Assets [Line Items]	'	'	'
Accumulated impairment losses	$0	'	'
Amortization expense	2,880	3,027	1,260
Total estimated amortization expense, 2014	2,748	'	'
Total estimated amortization expense, 2015	2,748	'	'
Total estimated amortization expense, 2016	2,749	'	'
Total estimated amortization expense, 2017	2,721	'	'
Total estimated amortization expense, 2018	2,641	'	'
Total estimateed amortization expense, thereafter	$13,449	'	'
Weighted Average | Patents and Related Technologies	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'
Weighted average useful life	'12 years 3 months 18 days	'	'

Intangible_Assets_Net_Schedule

Intangible Assets, Net - Schedule of Intangible Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$49,672	$34,988
Accumulated Amortization	-7,716	-5,482
Net	41,956	29,506
Patents and Related Technologies	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	34,772	34,342
Accumulated Amortization	-7,716	-4,851
Net	27,056	29,491
In- Process Research and Development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	14,900	'
Net	14,900	'
Favorable Rent Asset	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	'	646
Accumulated Amortization	'	-631
Net	'	$15

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Total domestic loss before income taxes	($39,250)	'	'
Total foreign loss before income taxes	-1,658	'	'
Income tax benefit recognized	0	0	0
Federal corporate income tax rate	34.00%	34.00%	34.00%
Operating losses subject to annual limits	16,400	'	'
Annual usage limit of operating loss carryforwards	1,500	'	'
Net operating losses inherited via acquisition	14,800	'	'
Operating loss carryforwards	242,318	'	'
Federal and state research and development tax credits	10,062	5,848	'
Expiration date of Federal income tax loss carryforwards	'2022	'	'
Share Based Compensation	'	'	'
Income Tax Disclosure [Abstract]	'	'	'
Operating loss carryforwards	2,636	'	'
INTREXON CORP	'	'	'
Income Tax Disclosure [Abstract]	'	'	'
Federal and state research and development tax credits	6,968	'	'
AquaBounty	'	'	'
Income Tax Disclosure [Abstract]	'	'	'
Annual usage limit of operating loss carryforwards	900	'	'
Federal and state research and development tax credits	3,000	'	'
Expiration date of Federal income tax loss carryforwards	'2019	'	'
AquaBounty | Federal	'	'	'
Income Tax Disclosure [Abstract]	'	'	'
Operating loss carryforwards	8,300	'	'
AquaBounty | Foreign	'	'	'
Income Tax Disclosure [Abstract]	'	'	'
Operating loss carryforwards	$4,100	'	'

Schedule_of_Effective_Income_T

Schedule of Effective Income Tax Rate Reconciliation (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Computed statutory income tax benefit	($13,909)	($27,837)	($28,995)
(Increase) reduction in income tax benefit resulting from State income tax benefit, net of federal income taxes	-1,834	-3,711	-3,893
Nondeductible stock based compensation	575	333	203
Contribution of services by shareholder	527	527	71
Gain in previously held equity investment	-2,477	'	'
Research and development tax credits	-1,203	'	-2,515
Other, net	1,317	-238	477
Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance, Total	-17,004	-30,926	-34,652
Change in valuation allowance for deferred tax assets	17,004	30,926	34,652
Total income tax provision	$0	$0	$0

Tax_Effects_of_Temporary_Diffe

Tax Effects of Temporary Differences Comprise Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Deferred tax assets	'	'	'	'
Equity securities	$415	$4,346	'	'
Accrued liabilities	1,445	1,910	'	'
Stock-based compensation	1,677	363	'	'
Deferred revenue	28,456	22,684	'	'
Research and development tax credits	10,062	5,848	'	'
Net operating loss carryforwards	97,395	80,159	'	'
Total deferred tax assets	139,450	115,310	'	'
Less: Valuation allowance	131,985	113,051	82,125	52,036
Net deferred tax assets	7,465	2,259	'	'
Deferred tax liabilities	'	'	'	'
Property and equipment	140	478	'	'
Intangible assets	7,325	1,781	'	'
Total deferred tax liabilities	7,465	2,259	'	'
Net deferred tax assets (liabilities)	'	'	'	'

Activity_of_Valuation_Allowanc

Activity of Valuation Allowance for Deferred Tax Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Valuation allowance at beginning of year	$113,051	$82,125	$52,036
(Decrease) increase in valuation allowance as a result of Mergers and acquisitions, net	1,930	'	-4,563
(Decrease) increase in valuation allowance as a result of current year operations	17,004	30,926	34,652
Valuation allowance at end of year	$131,985	$113,051	$82,125

Redeemable_Convertible_Preferr2

Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit) - Summary of Redeemable Convertible Preferred Stock (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Temporary Equity [Line Items]	'	'	'
Accretion of dividends	$18,391	$21,994	$13,868
Series A Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	1,358	802	'
Accretion of dividends	52	556	'
Conversion to common stock	-1,410	'	'
Ending Balance	'	1,358	'
Beginning Balance, Shares	705,400	705,400	'
Conversion to common stock, Shares	-705,400	'	'
Ending Balance, Shares	'	705,400	'
Series B Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	669	639	'
Accretion of dividends	19	30	'
Conversion to common stock	-688	'	'
Ending Balance	'	669	'
Beginning Balance, Shares	694,000	694,000	'
Conversion to common stock, Shares	-694,000	'	'
Ending Balance, Shares	'	694,000	'
Series B-1 Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	1,360	1,300	'
Accretion of dividends	37	60	'
Conversion to common stock	-1,397	'	'
Ending Balance	'	1,360	'
Beginning Balance, Shares	1,212,360	1,212,360	'
Conversion to common stock, Shares	-1,212,360	'	'
Ending Balance, Shares	'	1,212,360	'
Series C Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	7,134	6,729	'
Accretion of dividends	266	405	'
Conversion to common stock	-7,400	'	'
Ending Balance	'	7,134	'
Beginning Balance, Shares	4,546,360	4,546,360	'
Conversion to common stock, Shares	-4,546,360	'	'
Ending Balance, Shares	'	4,546,360	'
Series C-1 Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	34,201	32,264	'
Accretion of dividends	1,272	1,937	'
Conversion to common stock	-35,473	'	'
Ending Balance	'	34,201	'
Beginning Balance, Shares	15,934,528	15,934,528	'
Conversion to common stock, Shares	-15,934,528	'	'
Ending Balance, Shares	'	15,934,528	'
Series C-2 Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	44,512	41,987	'
Accretion of dividends	1,660	2,525	'
Conversion to common stock	-46,172	'	'
Ending Balance	'	44,512	'
Beginning Balance, Shares	18,617,020	18,617,020	'
Conversion to common stock, Shares	-18,617,020	'	'
Ending Balance, Shares	'	18,617,020	'
Series C-3 Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	29,770	28,082	'
Issuance of shares	'	'	'
Accretion of dividends	1,103	1,688	'
Stock issuance costs	'	'	'
Conversion to common stock	-30,873	'	'
Settlement of fractional shares upon conversion to common stock	'	'	'
Ending Balance	'	29,770	'
Beginning Balance, Shares	13,297,872	13,297,872	'
Conversion to common stock, Shares	-13,297,872	'	'
Settlement of fractional shares upon conversion to common stock	'	'	'
Ending Balance, Shares	'	13,297,872	'
Series D Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	76,252	71,924	'
Issuance of shares	'	'	'
Accretion of dividends	2,827	4,328	'
Stock issuance costs	'	'	'
Conversion to common stock	-79,078	'	'
Settlement of fractional shares upon conversion to common stock	-1	'	'
Ending Balance	'	76,252	'
Beginning Balance, Shares	19,803,685	19,803,685	'
Conversion to common stock, Shares	-19,803,685	'	'
Settlement of fractional shares upon conversion to common stock	'	'	'
Ending Balance, Shares	'	19,803,685	'
Series E Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	211,403	117,954	'
Issuance of shares	'	83,000	'
Accretion of dividends	7,931	10,465	'
Stock issuance costs	'	-16	'
Conversion to common stock	-219,332	'	'
Settlement of fractional shares upon conversion to common stock	-2	'	'
Ending Balance	'	211,403	'
Beginning Balance, Shares	38,095,239	22,285,716	'
Issuance of shares, Shares	'	15,809,523	'
Conversion to common stock, Shares	-38,095,239	'	'
Settlement of fractional shares upon conversion to common stock	'	'	'
Ending Balance, Shares	'	38,095,239	'
Series F Redeemable Convertible Preferred Stock	'	'	'
Temporary Equity [Line Items]	'	'	'
Beginning Balance	'	'	'
Issuance of shares	150,000	'	'
Accretion of dividends	3,224	'	'
Stock issuance costs	-3,148	'	'
Conversion to common stock	-150,075	'	'
Settlement of fractional shares upon conversion to common stock	-1	'	'
Ending Balance	'	'	'
Beginning Balance, Shares	'	'	'
Issuance of shares, Shares	19,047,619	'	'
Conversion to common stock, Shares	-19,047,619	'	'
Settlement of fractional shares upon conversion to common stock	'	'	'
Ending Balance, Shares	'	'	'

Redeemable_Convertible_Preferr3

Redeemable Convertible Preferred Stock and Shareholders' Equity (Deficit) - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 13, 2013	Dec. 31, 2012
Equity [Abstract]	'	'
Redemption price of arrearage amount	$68,850	$50,549
Redeemable convertible preferred stock	79,705,130	'

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Intrexon Stock Option Plan	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options outstanding	2,840,648	2,313,526	3,614,530	1,448,145
Term of issuance of option	'10 years	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%	'
Unrecognized compensation costs related to nonvested awards	$9,639	$4,910	$6,347	'
Recognized over weighted-average period	'3 years	'3 years	'3 years	'
Weighted average grant date fair value of options granted	$12.91	$4.60	$4.13	'
Aggregate intrinsic value of options exercised	1,136	913	264	'
Weighted average price of option	$8.27	$5.90	$5.22	$2.71
Options exercisable	1,227,563	'	'	'
Intrexon Stock Option Plan | Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Option issued, vesting period	'4 years	'	'	'
Intrexon Stock Option Plan | 2008 Plan	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of authorized awards	'	'	5,714,285	2,857,142
Options outstanding	2,554,648	'	'	'
Intrexon Stock Option Plan | 2013 Plan	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options outstanding	286,000	'	'	'
Shares of common stock reserved for issuance	7,000,000	'	'	'
Remaining shares available to grant	6,712,435	'	'	'
Intrexon Stock Option Plan | Research and Development Expense	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation cost	514	377	763	'
Intrexon Stock Option Plan | General and Administrative Expense	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation cost	2,298	1,081	220	'
AquaBounty Stock Option Plan	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options outstanding	6,624,000	'	'	'
Term of issuance of option	'10 years	'	'	'
Weighted average price of option	$0.25	'	'	'
Options exercisable	6,052,000	'	'	'
AquaBounty Stock Option Plan | Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Option issued, vesting period	'1 year	'	'	'
AquaBounty Stock Option Plan | Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Option issued, vesting period	'3 years	'	'	'
AquaBounty Stock Option Plan | General and Administrative Expense	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation cost	$109	'	'	'

Assumptions_Used_in_BlackSchol

Assumptions Used in Black-Scholes Option Pricing Model (Detail) (Intrexon Stock Option Plan)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, Minimum	73.00%	71.00%	68.00%
Expected volatility, Maximum	75.00%	76.00%	72.00%
Expected term (years)	'6 years 3 months	'6 years	'
Risk-free interest rate, Minimum	0.96%	0.80%	1.34%
Risk-free interest rate, Maximum	1.86%	1.10%	2.51%
Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term (years)	'	'	'6 years 2 months 23 days
Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term (years)	'	'	'5 years 4 months 13 days

Stock_Option_Plans_Schedule_of

Stock Option Plans - Schedule of Stock Option Activity (Detail) (Intrexon Stock Option Plan, USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Intrexon Stock Option Plan	'		'	'	'
Number of shares	'		'	'	'
Balances at beginning of period, Number of shares	2,313,526		3,614,530	1,448,145	'
Granted, Number of shares	989,709		548,571	2,429,684	'
Exercised, Number of shares	-88,764		-194,570	-75,840	'
Forfeited, Number of shares	-335,746		-1,210,857	-145,214	'
Expired, Number of shares	-38,077		-444,148	-42,245	'
Balances at period end, Number of shares	2,840,648		2,313,526	3,614,530	1,448,145
Exercisable, Number of shares	1,227,563		'	'	'
Vested and Expected to Vest, Number of shares	2,469,860	[1]	'	'	'
Weighted average exercise price	'		'	'	'
Balances at beginning of period, Weighted average exercise price	$5.90		$5.22	$2.71	'
Granted, Weighted average exercise price	$13.06		$7.12	$6.48	'
Exercised, Weighted average exercise price	($6.04)		($2.43)	($2.43)	'
Forfeited, Weighted average exercise price	($6.94)		($6.30)	($3.34)	'
Expired, Weighted average exercise price	($5.17)		($2.29)	($2.94)	'
Balances at period end, Weighted average exercise price	$8.27		$5.90	$5.22	$2.71
Exercisable, Weighted average exercise price	$5.37		'	'	'
Vested and Expected to Vest, Weighted average exercise price	$7.80	[1]	'	'	'
Weighted average remaining contractual term	'		'	'	'
Balances at period end, weighted average remaining contractual period	'7 years 9 months		'7 years 10 months 13 days	'6 years 8 months 1 day	'6 years 11 months 27 days
Exercisable at period end, weighted average remaining contractual period	'6 years 5 months 9 days		'	'	'
Vested and Expected to Vest at period end, weighted average remaining contractual period	'7 years 6 months 26 days	[1]	'	'	'
[1]	The number of stock options expected to vest takes into account an estimate of expected forfeitures

Summary_of_Information_About_S

Summary of Information About Stock Options Outstanding (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options outstanding, Number of Options	2,840,648	2,313,526
Options outstanding, Weighted average remaining life (years)	'7 years 9 months	'7 years 10 months 13 days
Options outstanding, Aggregate intrinsic value	$44,333	$2,845
Options exercisable, Number of Options	1,227,563	808,633
Options exercisable, Weighted average remaining life (years)	'6 years 5 months 9 days	'6 years 5 months 5 days
Options exerciseable, Aggregate intrinsic value	22,638	2,471
$0.39	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$0.39	$0.39
Options outstanding, Number of Options	57,263	57,263
Options outstanding, Weighted average remaining life (years)	'5 years 8 months 19 days	'8 years 26 days
Options outstanding, Aggregate intrinsic value	1,341	385
Options exercisable, Number of Options	57,263	57,263
Options exercisable, Weighted average remaining life (years)	'5 years 8 months 19 days	'8 years 26 days
Options exerciseable, Aggregate intrinsic value	1,341	385
$1.34	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$1.34	$1.34
Options outstanding, Number of Options	106,776	106,776
Options outstanding, Weighted average remaining life (years)	'2 years 1 month 6 days	'3 years 1 month 6 days
Options outstanding, Aggregate intrinsic value	2,398	617
Options exercisable, Number of Options	106,776	106,776
Options exercisable, Weighted average remaining life (years)	'2 years 1 month 6 days	'3 years 1 month 6 days
Options exerciseable, Aggregate intrinsic value	2,398	617
$1.92	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$1.92	$1.92
Options outstanding, Number of Options	12,855	23,145
Options outstanding, Weighted average remaining life (years)	'3 years 2 months 19 days	'4 years 3 months
Options outstanding, Aggregate intrinsic value	281	120
Options exercisable, Number of Options	12,855	23,145
Options exercisable, Weighted average remaining life (years)	'3 years 2 months 19 days	'4 years 3 months
Options exerciseable, Aggregate intrinsic value	281	120
$2.74	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$2.74	$2.74
Options outstanding, Number of Options	175,040	186,286
Options outstanding, Weighted average remaining life (years)	'3 years 7 months 28 days	'4 years 7 months 13 days
Options outstanding, Aggregate intrinsic value	3,686	815
Options exercisable, Number of Options	175,040	186,286
Options exercisable, Weighted average remaining life (years)	'3 years 7 months 28 days	'4 years 7 months 13 days
Options exerciseable, Aggregate intrinsic value	3,686	815
$3.29	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$3.29	$3.29
Options outstanding, Number of Options	156,055	183,442
Options outstanding, Weighted average remaining life (years)	'6 years 1 month 21 days	'6 years 9 months 7 days
Options outstanding, Aggregate intrinsic value	3,201	703
Options exercisable, Number of Options	143,411	126,014
Options exercisable, Weighted average remaining life (years)	'6 years 1 month 6 days	'6 years 8 months 19 days
Options exerciseable, Aggregate intrinsic value	2,941	483
$5.91	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$5.91	$5.91
Options outstanding, Number of Options	150,062	169,857
Options outstanding, Weighted average remaining life (years)	'7 years 1 month 24 days	'7 years 7 months 21 days
Options outstanding, Aggregate intrinsic value	2,685	205
Options exercisable, Number of Options	75,771	42,571
Options exercisable, Weighted average remaining life (years)	'7 years 26 days	'7 years 7 months 2 days
Options exerciseable, Aggregate intrinsic value	1,356	51
$7.12	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$7.12	$7.12
Options outstanding, Number of Options	1,194,887	1,586,757
Options outstanding, Weighted average remaining life (years)	'7 years 9 months 18 days	'8 years 9 months 7 days
Options outstanding, Aggregate intrinsic value	19,931	'
Options exercisable, Number of Options	546,805	266,578
Options exercisable, Weighted average remaining life (years)	'7 years 9 months 7 days	'8 years 6 months 11 days
Options exerciseable, Aggregate intrinsic value	9,121	'
$9.67	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$9.67	'
Options outstanding, Number of Options	701,710	'
Options outstanding, Weighted average remaining life (years)	'9 years 4 months 28 days	'
Options outstanding, Aggregate intrinsic value	9,915	'
Options exercisable, Number of Options	107,142	'
Options exercisable, Weighted average remaining life (years)	'9 years 4 months 28 days	'
Options exerciseable, Aggregate intrinsic value	1,514	'
$19.83	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$19.83	'
Options outstanding, Number of Options	225,500	'
Options outstanding, Weighted average remaining life (years)	'9 years 11 months 16 days	'
Options outstanding, Aggregate intrinsic value	895	'
Options exercisable, Number of Options	'	'
Options exerciseable, Aggregate intrinsic value	'	'
$26.76	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$26.76	'
Options outstanding, Number of Options	42,500	'
Options outstanding, Weighted average remaining life (years)	'9 years 8 months 9 days	'
Options outstanding, Aggregate intrinsic value	'	'
Options exercisable, Number of Options	'	'
Options exerciseable, Aggregate intrinsic value	'	'
$28.69	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise price	$28.69	'
Options outstanding, Number of Options	18,000	'
Options outstanding, Weighted average remaining life (years)	'9 years 7 months 13 days	'
Options outstanding, Aggregate intrinsic value	'	'
Options exercisable, Number of Options	2,500	'
Options exercisable, Weighted average remaining life (years)	'9 years 7 months 13 days	'
Options exerciseable, Aggregate intrinsic value	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Operating Leases Future Minimum Payments Due [Abstract]	'
2014	$3,661
2015	3,408
2016	2,687
2017	1,419
2018	72
Operating Leases, Future Minimum Payments Due, Total	$11,247

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Mar. 15, 2013
				AquaBounty	AquaBounty
Commitment And Contingencies [Line Items]	'	'	'	'	'
Rent expenses	$5,577	$5,036	$4,000	'	'
Rental income under sublease agreement	365	151	158	'	'
Future rental income for the sublease agreement in 2014	365	'	'	'	'
Future rental income for the sublease agreement in 2015	152	'	'	'	'
Amount available under the grant for Research and Development	'	'	'	2,685	'
Claims period	'	'	'	'5 years	'
Royalty on products	'	'	'	10.00%	'
Amount claimed	'	'	'	1,653	1,952
Amount claimed fair value	'	'	'	'	1,107
Accreted difference between face value of amount drawn and acquisition date fair value	'	'	'	845	'
Subsequent claims of financial grant	'	'	'	486	'
AquaBounty funding	'	'	'	$2,772	'
Percentage of royalty on revenues	'	'	'	5.20%	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

2 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 06, 2011

Apr. 08, 2011

26-May-11

Jun. 06, 2012

26-May-11

Aug. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 29, 2013

Jan. 20, 2012

Feb. 07, 2011

Jan. 06, 2011

Dec. 31, 2013

Dec. 17, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Nov. 20, 2013

Oct. 31, 2013

Affiliates Of Third Security

Affiliates Of Third Security

Affiliates Of Third Security

Affiliates Of Third Security

Affiliates Of Third Security

Cyntellect, Inc.

Cyntellect, Inc.

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Affiliates of Certain Shareholders

Affiliates of Certain Shareholders

Affiliates of Certain Shareholders

Shareholder

Shareholder

Shareholder

Ziopharm

Ziopharm

Ziopharm

Ziopharm

Ziopharm

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Oragenics, Inc

Oragenics, Inc

Oragenics, Inc

Fibrocell Science, Inc.

Series E Redeemable Convertible Preferred Stock

General and Administrative Expense

Office

Office

Share Purchase Rights Plan

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory notes issued

'

'

'

'

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Simple interest rate on promissory notes

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings on convertible promissory notes

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest on notes

'

'

'

'

'

165

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for conversion of convertible promissory notes

'

'

'

'

'

'

'

2,888,635

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date of a promissory note

'

'

'

'

'Terms of the notes included 12% simple interest annually with principal and interest due on or before June 30, 2011.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of license fee

'

'

'

9,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual exclusivity fee

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone payments

'

'

'

'

'

'

54,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Termination period

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during the period, shares for purchase of assets

'

'

'

'

'

'

'

'

2,386,803

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during the period, value for purchase of assets

'

'

'

'

'

'

'

'

17,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Costs associated with asset purchase

'

'

'

'

'

'

'

'

'

128

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense

'

'

'

'

'

'

'

'

'

'

1,550

1,550

210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company leased facility

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other long term assets

'

'

'

'

'

'

'

'

'

'

'

'

'

66

66

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent and other facility expenses

5,577

5,036

4,000

'

'

'

'

'

'

'

'

'

'

918

903

783

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party expense incurred on research and clinical services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152

91

202

'

'

'

'

'

'

'

'

'

'

'

Related party expense amount payable on research and clinical services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock purchased from collaborative partners

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,857,143

1,923,075

1,910,000

2,426,235

'

2,000,000

'

1,300,000

'

1,100,000

2,439,024

Price per share of common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

$5.20

$5.75

$4.80

'

$1

'

$3

'

$2.50

$4.10

Purchase of additional common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Purchase commitment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19,000

'

'

'

'

'

'

Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19.99%

'

30.00%

'

'

Additional shares of collaborative partner to which the entity is entitled to purchase on the open market

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

Carrying_Amount_of_Assets_Acqu

Carrying Amount of Assets Acquired and Liabilities Assumed (Detail) (Cyntellect, Inc., USD $)	Aug. 31, 2011
In Thousands, unless otherwise specified
Cyntellect, Inc.	'
Related Party Transaction [Line Items]	'
Cash	$88
Other current assets	23
Property and equipment, net	1,724
Other assets	262
Total assets acquired	2,097
Accounts payable	41
Other accrued liabilities	107
Long-term debt	116
Total liabilities assumed	264
Net assets acquired	$1,833

Net_Loss_Per_Share_Historical_

Net Loss Per Share - Historical Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator:	'	'	'	'	'	'	'	'	'	'	'
Net loss	'	'	'	'	'	'	'	'	($38,980)	($81,874)	($85,280)
Add: Accretion of dividends on redeemable convertible preferred stock	'	'	'	'	'	'	'	'	-18,391	-21,994	-13,868
Net loss attributable to common shareholders	($12,204)	$15,440	($5,905)	($36,311)	'	'	'	'	($57,371)	($103,868)	($99,148)
Denominator:	'	'	'	'	'	'	'	'	'	'	'
Weighted average shares outstanding, basic and diluted	'	'	'	'	'	'	'	'	40,951,952	5,533,690	5,240,647
Net loss attributable to common shareholders per share, basic and diluted	'	'	'	'	($6.52)	($4.66)	($3.99)	($3.55)	($1.40)	($18.77)	($18.92)

Net_Loss_Per_Share_Potentially

Net Loss Per Share - Potentially Dilutive Securities Excluded from Calculation of Net Income (Loss) per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	3,255,052	67,342,601	59,609,594
Common Shares Issuable Upon Conversion of All Series Preferred	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	64,517,977	55,483,966
Options	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	2,840,648	2,313,526	3,614,530
Warrant	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	414,404	511,098	511,098

Quarterly_Financial_Informatio2

Quarterly Financial Information - Selected Financial Information from Unaudited Consolidated Statements Including Recurring Adjustments (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$7,143	$6,042	$6,690	$3,885	$6,569	$2,925	$2,716	$1,564	$23,760	$13,774	$8,013
Operating loss	-17,726	-12,037	-14,254	-14,006	-12,303	-16,485	-21,248	-25,121	-58,023	-75,157	-82,427
Net income (loss)	-13,018	14,991	-6,519	-36,362	-30,937	-20,490	-16,535	-13,912	-40,908	-81,874	-85,280
Net income (loss) attributable to Intrexon	($12,204)	$15,440	($5,905)	($36,311)	'	'	'	'	($57,371)	($103,868)	($99,148)
Net loss attributable to common shareholders per share, basic and diluted	'	'	'	'	($6.52)	($4.66)	($3.99)	($3.55)	($1.40)	($18.77)	($18.92)
Net income (loss) attributable to common shareholders per share, basic	($0.13)	$0.15	($2.44)	($7.54)	'	'	'	'	'	'	'
Net income (loss) attributable to common shareholders per share, diluted	($0.13)	$0.15	($2.44)	($7.54)	'	'	'	'	'	'	'

Defined_Contribution_Plan_Addi

Defined Contribution Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation And Retirement Disclosure [Abstract]	'	'	'
Defined Contribution Plan,Cost Recognized	$598	$755	$433

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 15, 2013	Mar. 26, 2014	Mar. 04, 2014	Mar. 20, 2014	Mar. 26, 2014	Mar. 06, 2014	Mar. 20, 2014
In Thousands, except Share data, unless otherwise specified		Intrexon Stock Option Plan	Intrexon Stock Option Plan	Intrexon Stock Option Plan	AquaBounty	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
								Intrexon Stock Option Plan	Intrexon Energy Partners, LLC	Medistem, Inc.	AquaBounty
								2013 Plan	Upfront and Milestone Payments
									Upfront
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Lease termination period	'	'	'	'	'	'	'7 years	'	'	'	'
Annual rental payments due 2015	$3,408	'	'	'	'	'	$575	'	'	'	'
Annual rental payments due 2016	2,687	'	'	'	'	'	1,153	'	'	'	'
Annual rental payments due 2017	1,419	'	'	'	'	'	1,188	'	'	'	'
Annual rental payments due 2018	72	'	'	'	'	'	1,223	'	'	'	'
Thereafter	'	'	'	'	'	'	3,665	'	'	'	'
Business acquisition purchase price	'	'	'	'	'	'	'	'	'	24,600	'
Business acquisition, cash price per share	'	'	'	'	'	'	'	'	'	$0.27	'
Business acquisition shares, share price	'	'	'	'	'	'	'	'	'	$1.08	'
Business acquisition, shares exchange ratio	'	'	'	'	'	'	'	'	'	0.0392	'
Number of shares acquired	'	'	'	'	18,714,814	'	'	'	'	'	19,040,366
Amount from private subscription offering	'	'	'	'	4,907	'	'	'	'	'	10,000
Aggregate percentage of ownership	'	'	'	'	53.82%	'	'	'	'	'	59.85%
Granted, Number of shares	'	989,709	548,571	2,429,684	'	'	'	5,950,000	'	'	'
Authorized increase in number of shares reserved for issuance, subject to shareholder approval	'	'	'	'	'	'	'	3,000,000	'	'	'
Collaborative arrangement consideration received, value	'	'	'	'	'	'	'	'	25,000	'	'
Securities purchase agreements, share	'	'	'	'	'	972,004	'	'	'	'	'
Securities purchase agreements, price per share	'	'	'	'	'	$25.72	'	'	'	'	'
Securities purchase agreements gross proceed	'	'	'	'	'	$25,000	'	'	'	'	'